Immuron Limited (IMRN) 20-F 1 Oct 24 2024 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jun. 30, 2024 shares
Document Information Line Items
Entity Registrant Name	IMMURON LIMITED
Trading Symbol	IMRN
Document Type	20-F
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding	227,998,346
Amendment Flag	false
Entity Central Index Key	0001660046
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	000-38104
Entity Incorporation, State or Country Code	C3
Entity Address, Address Line One	Level 3, 62 Lygon Street
Entity Address, Address Line Two	Carlton South
Entity Address, City or Town	Victoria
Entity Address, Postal Zip Code	3053
Entity Address, Country	AU
Title of 12(b) Security	American Depositary Shares, each representing 40 Ordinary Shares
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	2233
Auditor Name	GRANT THORNTON AUDIT PTY LTD
Auditor Location	Melbourne, Australia
Business Contact
Document Information Line Items
Entity Address, Address Line One	Level 3, 62 Lygon Street
Entity Address, Address Line Two	Carlton South
Entity Address, City or Town	Victoria
Entity Address, Postal Zip Code	3053
Entity Address, Country	AU
Contact Personnel Name	Mr. Steven Lydeamore
City Area Code	61
Local Phone Number	3 9824 5254

Consolidated Statement of Profi

Consolidated Statement of Profit or Loss and Other Comprehensive Income - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Profit or loss [abstract]
Revenue from contracts with customers	$ 4,902,865	$ 1,804,705	$ 765,193
Cost of Goods Sold	(1,566,068)	(495,558)	(241,691)
Gross Profit	3,336,797	1,309,147	523,502
Grant Income	3,408,199	2,591,498	957,725
Fair value (losses) to financial assets	(557,676)	(523,666)
Net foreign exchange gains/(losses)	(27,603)	363,724	247,558
Movement in inventory provision		430,932
Expenses
General and administrative expenses	(4,555,726)	(4,220,905)	(3,524,388)
Research and development expenses	(5,375,461)	(2,592,145)	(657,715)
Selling and marketing expenses	(2,029,648)	(927,423)	(416,537)
Operating loss	(5,801,118)	(3,568,838)	(2,869,855)
Finance income	327,756	116,323	21,785
Finance expenses	(7,576)	(9,652)	(6,184)
Finance costs - net	320,180	106,671	15,601
Share of loss from associates	(1,456,019)	(324,340)
Loss Before Income Tax	(6,936,957)	(3,786,507)	(2,854,254)
Income tax expense
Loss for the Period	(6,936,957)	(3,786,507)	(2,854,254)
Items that may be reclassified to profit or loss:
Exchange differences on translation of foreign operations	2,266	(1,012)	6,708
Total Comprehensive Loss for the Period	$ (6,934,691)	$ (3,787,519)	$ (2,847,546)
Basic Loss per Share (in cents per share) (in Dollars per share)	$ (3.04)	$ (1.66)	$ (1.25)

Consolidated Statement of Pro_2

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Parentheticals) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Profit or loss [abstract]
Diluted Loss per Share (in cents per share)	$ (3.04)	$ (1.66)	$ (1.25)

Consolidated Statement of Finan

Consolidated Statement of Financial Position	Jun. 30, 2024 AUD ($)	Jun. 30, 2023 AUD ($)
Current Assets
Cash and cash equivalents	$ 11,657,315	$ 17,159,764
Trade and other receivables	1,387,573	417,420
Inventories	1,584,608	839,968
Financial assets		1,834,034
Other current assets	96,841	158,151
Total Current Assets	14,726,337	20,409,337
Non-Current Assets
Investments accounted for using the equity method		159,066
Property, plant and equipment	154,347	200,133
Inventories	669,285	1,219,646
Total Non-Current Assets	823,632	1,578,845
TOTAL ASSETS	15,549,969	21,988,182
Current Liabilities
Trade and other payables	2,135,852	1,192,769
Employee benefit obligations	522,571	289,408
Deferred income		698,195
Other current liabilities	40,556	38,767
Total Current Liabilities	2,698,979	2,219,139
Non-Current Liabilities
Employee benefit obligations	8,605	1,882
Other non-current liabilities	132,941	150,325
Total Non-Current Liabilities	141,546	152,207
TOTAL LIABILITIES	2,840,525	2,371,346
NET ASSETS	12,709,444	19,616,836
EQUITY
Issued capital	88,504,043	88,436,263
Reserves	3,173,797	3,235,969
Accumulated losses	(78,968,396)	(72,055,396)
TOTAL EQUITY	$ 12,709,444	$ 19,616,836

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - AUD ($)	Issued Capital	Reserves	Accumulated Losses	Total
Balance at Jun. 30, 2021	$ 88,361,303	$ 3,466,642	$ (65,932,888)	$ 25,895,057
Loss after income tax expense for the year			(2,854,254)	(2,854,254)
Other comprehensive income for the period		6,708		6,708
Total comprehensive loss for the period		6,708	(2,854,254)	(2,847,546)
Shares issued, net of costs	74,960			74,960
Options/warrants issued/expensed (net of adjustments)		54,930		54,930
Options/warrants lapsed/exercised		(361,861)	361,861
Balance at Jun. 30, 2022	88,436,263	3,166,419	(68,425,281)	23,177,401
Loss after income tax expense for the year			(3,786,507)	(3,786,507)
Other comprehensive income for the period		(1,012)		(1,012)
Total comprehensive loss for the period		(1,012)	(3,786,507)	(3,787,519)
Options/warrants issued/expensed (net of adjustments)		104,753		104,753
Options/warrants lapsed/expired		(156,392)	156,392
Performance rights issued/expensed		122,201		122,201
Balance at Jun. 30, 2023	88,436,263	3,235,969	(72,055,396)	19,616,836
Loss after income tax expense for the year			(6,936,957)	(6,936,957)
Other comprehensive income for the period		2,266		2,266
Total comprehensive loss for the period		2,266	(6,936,957)	(6,934,691)
Unlisted options issued/expensed		15,231		15,231
Options/warrants issued/expensed (net of adjustments)		(11,932)		(11,932)
Options/warrants exercised	67,780	(43,780)		24,000
Options/warrants forfeited		(23,957)	23,957
Balance at Jun. 30, 2024	$ 88,504,043	$ 3,173,797	$ (78,968,396)	$ 12,709,444

Consolidated Statement of Cash

Consolidated Statement of Cash Flows	12 Months Ended
	Jun. 30, 2024 AUD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)
Cash Flows Related to Operating Activities
Receipts from customers	$ 4,734,350	$ 1,912,689	$ 696,603
Payments to suppliers and employees	(12,910,753)	(7,842,052)	(4,629,139)
Australian R&D tax incentive refund	395,001	251,986	306,154
Grants received from government and non-government sources	1,901,263	3,082,182	478,589
Net Cash Flows Used In Operating Activities	(5,880,139)	(2,595,195)	(3,147,793)
Cash Flows Related to Investing Activities
Payments for purchases of plant and equipment	(195)	(7,739)	(10,048)
Payments for acquisition of associate		(2,729,863)
Interest received	327,756	116,323	21,785
Net Cash Flows From/(Used In) Investing Activities	327,561	(2,621,279)	11,737
Cash Flows Related to Financing Activities
Proceeds from issues of securities	24,000
Principal elements of lease payments	(15,595)	(35,015)	(36,264)
Interest and other costs of finance paid	(7,576)	(9,652)	(6,184)
Net Cash Flows From/(Used In) Financing Activities	829	(44,667)	(42,448)
Net (decrease)/increase in cash and cash equivalents	(5,551,749)	(5,261,141)	(3,178,504)
Cash and cash equivalents at the beginning of the year	17,159,764	22,110,278	25,047,281
Effects of exchange rate changes on cash and cash equivalents	49,300	310,627	241,501
Cash and Cash Equivalents at the End of the Year	$ 11,657,315	$ 17,159,764	$ 22,110,278

Summary of Material Accounting

Summary of Material Accounting Policies	12 Months Ended
	Jun. 30, 2024
Summary of Material Accounting Policies [Abstract]
Summary of Material Accounting Policies	Note 1. Summary of Material Accounting Policies Corporate Information The consolidated financial report of Immuron Limited (“the Company”) for the year ended June 30, 2024, 2023 and 2022 was authorized for issue in accordance with a resolution of the Directors on September 30, 2024. Immuron Limited is a listed public company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (“ASX”) and The NASDAQ Capital Market (“NASDAQ”). The group’s principal activity is oral immunotherapy research and development and product sales focused on bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infectious diseases. Product sales comprise Travelan which is indicated to reduce the risk of contracting travelers’ diarrhea and Protectyn an OTC immune supplement for GI tract and liver health. (a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the Corporations Act 2001 (i) Compliance with IFRS The consolidated financial statements of the Immuron Limited group also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). (ii) Historical cost convention The financial statements have been prepared on a historical cost basis. (iii) Going concern The group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the group not continue as a going concern. This note provides a list of the material accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the group consisting of Immuron Limited and its subsidiaries. (iv) New standards and interpretations not yet adopted There are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future transactions. Summary of material accounting policies The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated. (b) Principles of consolidation and equity accounting (i) Subsidiaries Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the group. Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. (ii) Associates Associates are all entities over which the group has significant influence but not control or joint control. Investments in associates are accounted for using the equity method of accounting (see (iii) below), after initially being recognized at cost. On initial recognition, where an associate meets the definition of a business, AASB 3 Business Combinations applied by analogy. (iii) Equity method Under the equity method, the share of the profits or losses of the associate is recognized in profit or loss and the share of the movements in equity is recognized in other comprehensive income. Investments in associates are carried in the statement of financial position at cost plus post-acquisition changes in the group’s share of net assets of the associate. Goodwill relating to the associate is included in the carrying amount of the investment and is neither amortized nor individually tested for impairment. Dividends received or receivable from associates reduce the carrying amount of the investment. When the group’s share of losses in an associate equal or exceeds its interest in the associate, including any unsecured long-term receivables, the group does not recognize further losses, unless it has incurred obligations or made payments on behalf of the associate. The Group reports impairment losses of associates within the share of loss from associates. (iv) Changes in ownership interests The group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the group. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognized in a separate reserve within equity attributable to owners of Immuron Limited. When the group ceases to consolidate or equity account for an investment because of a loss of control, joint control or significant influence, any retained interest in the entity is remeasured to its fair value with the change in carrying amount recognized in profit or loss. This fair value becomes the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate or financial asset. In addition, any amounts previously recognized in other comprehensive income in respect of that entity are accounted for as if the group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognized in other comprehensive income are reclassified to profit or loss. If the ownership interest in an associate is reduced but joint control or significant influence is retained, only a proportionate share of the amounts previously recognized in other comprehensive income are reclassified to profit or loss where appropriate. (c) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive management team consisting of the CEO, COO and CCO. Management considers the business from both a product and a geographic perspective and has identified two reportable segments: Research and development (R&D) and Hyper-immune products. See Note 15 for more details. (d) Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the group’s entities are measured using the currency of the primary economic environment in which the entity operates (‘the functional currency’). The consolidated financial statements are presented in Australian dollar (“A$” or “$”), which is Immuron Limited’s functional and presentation currency. (ii) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within other gains/(losses). Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income. (iii) Group companies The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● assets and liabilities for each consolidated balance sheet presented are translated at the closing rate at the date of that consolidated balance sheet; ● income and expenses for each consolidated statement of profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and ● all resulting exchange differences are recognized in other comprehensive income. On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale. (e) Income and revenue recognition (i) Sale of hyper-immune products Revenue arises mainly from the sale of hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when performance obligations are satisfied. Revenue from the sale of hyperimmune products is recognized at a point in time when or as the group transfers control of the assets to the customer upon delivery of the products or in the case of consignment sales when the distributor sells the product to the customer. The general standard payments terms for customers are 30 days. There is no significant cost to obtain the contract. However, there is variable consideration due to rebates, discounts and refunds. The variable amount of consideration is allocated entirely to the distinct good that is consistent with the amount of consideration to which the group expects to be entitled in exchange for transferring the promised goods to the customer. The group offers rebates of up to 15% to some loyal customers in Australia. There are no warranties. Returns and refunds are provided where this is outlined in a customer agreement. The group does not have a formal policy in place relating to stock returns. In cases where we have a contract in place with a distributor, and that contract includes a stock return policy, we will adhere to the policy listed in the contract. For all other distributors, stock returns are negotiated on a case-by-case basis. The exception to this is where stock is short dated to within 3 months. In this case we will offer replacement stock or a refund. (ii) Financing components The group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money. (f) Grants from government and non-government sources Grants are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the group will comply with all attached conditions. Other income amounts are recognized when it has been established that the conditions of the grants have been met and that the expected amount can be reliably measured. Grants are recognized in profit or loss on a systematic basis over the periods in which the Group recognizes as expenses the related costs for which the grants are intended to compensate. (i) Accrued receivables These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive. (ii) Research and development (“R&D”) grants from MTEC The group’s other grant income is recognized when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received and the amount can be reliably measured. For the year ended 30 June 2024, the group has recognized $2,599,458 (2023: $2,158,936) R&D grant from Medical Technology Enterprise Consortium (“MTEC”). These grants are recognized in profit or loss on a systematic basis over the periods in which the Group recognizes as expenses the related costs for which the grants are intended to compensate. (iii) Deferred income Government grants and other grants relating to costs are deferred and recognized in profit or loss over the period necessary to match them with the costs that they are intended to compensate. (g) Income tax The income tax expense or credit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. As per IFRIC 23 Uncertainty over Income Tax Treatments, where it is probable, the group has determined tax balances consistently with the tax treatment used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending on which method is expected to better predict the resolution of the uncertainty). (h) Leases Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: ● fixed payments (including in-substance fixed payments), less any lease incentives receivable ● variable lease payment that are based on an index or a rate ● amounts expected to be payable by the lessee under residual value guarantees ● the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and ● payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the group’s incremental borrowing rate. Right-of-use assets are measured at cost comprising the following: ● the amount of the initial measurement of lease liability ● any lease payments made at or before the commencement date, less any lease incentives received ● any initial direct costs, and ● restoration costs. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short- term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture. (i) Business combinations Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognized and also recognizes additional assets and liabilities during the measurement period, based on new information obtained about facts and circumstances that existed at acquisition date. The measurement period ends on either the earlier of (i) 12 months from the date of acquisition or (ii) when the acquirer receives all the information possible to determine fair value. Acquired assets and liabilities are initially recognized at their fair value. Any excess consideration paid is recognized as goodwill. Any excess net assets relative to consideration paid is recognized as a gain or bargain purchase. Consideration paid, including any contingent assets and liabilities acquired, are initially and subsequently measured at fair value. Any changes in fair value of contingent consideration payable or receivable are recognized as gain or loss on the income statement. (j) Impairment of assets An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash- generating units). Non-financial assets that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period. (k) Cash and cash equivalents For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the consolidated balance sheet. (l) Trade receivables Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less loss allowance. The group applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 60 months before June 30, 2024 and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. (i) Classification as trade receivables Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with the objective of collecting the contractual cash flows and therefore measures them subsequently at amortized cost using the effective interest method. Details about the group’s impairment policies and the calculation of the loss allowance are provided below. (ii) Fair value of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value. (iii) Risk management The Group’s risk management is predominantly controlled by the Board. The Board monitors the Group’s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk. The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Company’s implementation of that system on a regular basis. The Board and Senior Management identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review of: Ø the major risks that occur within the business; the degree of risk involved; Ø the current approach to managing the risk; and Ø if appropriate, determine: ○ any inadequacies of the current approach; and ○ possible new approaches that more efficiently and effectively address the risk. Management report risks identified to the Board through the monthly Operations Report. The Company seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimized in a cost effective manner. (m) Inventories (i) Raw materials and stores, work in progress and finished goods Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises of direct materials, direct labor and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. (n) Investments and other financial assets (i) Classification The group classifies its financial assets in the following measurement categories: ● those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss); and ● those to be measured at amortized cost. The classification depends on the group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). (ii) Recognition and derecognition Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership. (iii) Measurement At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss. (iv) Impairment The group assesses on a forward-looking basis the expected credit losses associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables, the group applies the simplified approach permitted by AASB 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables. (v) Income recognition - Interest income Interest income is recognized using the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount as interest income. Interest income on impaired loans is recognized using the original effective interest rate. (o) Property, plant and equipment Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter of the useful life of the asset and the term of lease as follows: ● Plant and equipment 2 - 5 years ● Furniture, fittings and equipment 3 - 15 years ● Right-of-use assets 3 years The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss. (p) Intangible assets (i) Research and development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred. (q) Trade and other payables These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method. (r) Employee benefits (i) Short-term obligations Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet. (ii) Other long-term employee benefit obligations In some countries, the group also has liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Share-based payments Share-based compensation benefits are provided to employees via the Omnibus Incentive Plan (OIP). Employee options The fair value of options granted under the OIP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted: - including any market performance conditions (e.g. the company’s share price); - excluding the impact of any service and non-market performance vesting conditions (e.g.

Critical Accounting Estimates a

Critical Accounting Estimates and Judgments	12 Months Ended
	Jun. 30, 2024
Critical Accounting Estimates and Judgments [Abstract]
Critical Accounting Estimates and Judgments	Note 2. Critical Accounting Estimates and Judgments Management evaluates estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both internally and externally. Impairment in other associates Arteria Health Limited Impairment of associates requires a degree of estimation and judgment. After application of the equity method, the Group considers conditions and evidence that its net investment in the associate is impaired. If an impairment trigger event exists, the recoverable amount of the associate is determined. This involves fair value less costs of disposal or value in use calculations, which incorporates a number of key estimates and assumptions. Refer to Note 10(b) for further information Share-based payments The value attributed to share options and remunerations shares issued is an estimate calculated using an appropriate mathematical formula based on an option pricing model. The choice of models and the resultant option value require assumptions to be made in relation to the likelihood and timing of the conversion of the options to shares and the value of volatility of the price of the underlying shares. Refer to Note 17 for further information The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. Impairment of inventories The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf- life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability study was completed in August 2020 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance. Refer to Note 9(b)i for further information Presentation of Inventory During the year ended 30 June 2024, management performed an assessment of its raw materials and utilization within 12 months from reporting date. Management determined $139,745 (2023: nil) of raw materials relating to Colostrum on hand held in Immuron’s warehouse will be consumed within 12 months from reporting date. An amount of $669,285 (2023:$1,108,256) of raw materials would be consumed beyond 12 months. R&D tax incentive The Group’s research and development activities are eligible under an Australian Government tax incentive for eligible expenditure from July 1, 2011. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Refer to Note 3 for further information Fair value measurement The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments, estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgments, estimates, and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgments and estimates will seldom equal the related actual results. The judgments, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed within the relevant sections where applicable. Refer to Note 8(c) for further information Investment in Ateria The acquisition of the interest in Ateria gains the Group a right to one board seat. If the Ateria contingent consideration receivable is received and the option to acquire shares were exercised (refer to Note 8(c) and 10(b)), Ateria’s shareholding would increase, and an additional board seat would be received. Management did not exercise the option by the expiry date of 31 July 2023. Management has therefore determined that Immuron does not and could not exercise control over Ateria. Mr Lydeamore was a Director of Ateria from 25 November 2022, resigning on 1 May 2024 to focus his attention on the Company.

Revenue and Other Income

Revenue and Other Income	12 Months Ended
	Jun. 30, 2024
Revenue and Other Income [Abstract]
Revenue and other income	Note 3. Revenue and other income 30 June 30 June 30 June Notes A$ A$ A$ Revenue Revenue from Operating Activities Revenue from contracts with customers at a point in time 4,902,865 1,804,705 765,193 Total Revenue from Operating Activities 4,902,865 1,804,705 765,193 Grant Income Australian R&D tax incentive refund 764,981 392,877 257,500 MTEC R&D grant 2,599,458 2,158,936 369,045 HJF R&D grant - - 306,595 EMDG grant 28,000 28,000 - Other income 15,760 11,685 24,585 Total Grant Income 3,408,199 2,591,498 957,725 Other Gains/(Losses) – Net Fair value gains/(losses) to financial assets 8 (c)(ii) (557,676 ) (523,666 ) - Net foreign exchange gains/(losses) (27,603 ) 363,724 247,558 Movement in inventory provision - 430,932 - (i) Fair value of R&D tax incentive refund The group’s R&D activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognized when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. (ii) R&D grants from MTEC The group’s other grant income is recognized when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received and the amount can be reliably measured. For the year ended 30 June 2024, the group has recognized $2,599,458 (2023: $2,158,936) R&D grant from Medical Technology Enterprise Consortium (“MTEC”). This is to recognize income over the year necessary to match the grants on a systematic basis with the costs that they are intended to compensate.

Expenses

Expenses	12 Months Ended
	Jun. 30, 2024
Expenses [Abstract]
Expenses	Note 4. Expenses 30 June 30 June 30 June 2024 2023 2022 General and administrative expenses Accounting and audit 576,540 657,970 499,331 Bad debts - 2,376 - Consulting 120,851 23,241 226,710 Depreciation 45,981 48,662 42,606 Employee benefits 2,353,625 1,874,963 1,212,721 Expected credit losses (11,687 ) 19,111 8,809 Insurance 321,679 434,699 401,121 Investor relations 206,300 194,754 38,567 Legal 195,971 233,243 520,698 Listing and share registry 163,949 152,954 164,949 Superannuation 180,092 141,539 62,647 Travel and entertainment 196,369 105,535 9,459 Share-based payment expenses - options 3,299 104,753 94,890 Share-based payment expenses - performance rights - 122,201 - Occupancy 24,122 - - Other 178,635 104,904 241,880 4,555,726 4,220,905 3,524,388 Research and development expenses Consulting 277,128 111,530 230,684 Project research and development 5,098,333 2,480,615 427,031 5,375,461 2,592,145 657,715 Selling and marketing expenses Selling 379,406 192,878 57,854 Marketing 1,310,979 474,926 113,472 Distribution costs 339,263 259,619 245,211 2,029,648 927,423 416,537

Income Tax Expense

Income Tax Expense	12 Months Ended
	Jun. 30, 2024
Income Tax Expense [Abstract]
Income Tax Expense	Note 5. Income Tax Expense 30 June 30 June 2024 2023 Unused tax losses for which no deferred tax asset has been recognized 59,447,397 52,625,541 Potential tax benefit 25% (2023: 25%) 14,861,849 13,156,385 The above potential tax benefit for tax losses has not been recognized in the statement of financial position. These tax losses can only be utilized in the future if the continuity of ownership test is passed, or failing that, the same business test is passed. The taxation benefits of tax losses and temporary difference not brought to account will only be obtained if: (i) the entity derives future assessable income of a nature and of an amount sufficient to enable the benefit from the deductions for the losses to be realized; (ii) the entity continues to comply with the conditions for deductibility imposed by law; and (iii) no change in tax legislation adversely affects the entity in realizing the benefits from deducting the losses. The group operates in different tax jurisdictions and continues to meet its statutory requirements in these jurisdictions. The tax losses in each jurisdiction are subject to testing to make sure they meet all relevant statutory tests for them to be offset against future income. Numerical reconciliation of income tax expense to prima facie tax payable 30 June 30 June Loss from continuing operations before income tax expense (6,936,957 ) (3,786,507 ) Tax at the Australian tax rate of 25% (2023: 25%) (1,734,239 ) (946,627 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: R&D tax incentive (191,245 ) (98,219 ) Accounting expenditure subject to R&D tax incentive 439,644 225,791 Share-based payments 825 56,738 Net impact of other amounts not deductible (taxable) (220,449 ) (453,038 ) Subtotal (1,705,464 ) (1,215,355 ) Tax losses and other timing differences for which no deferred tax asset is recognized 1,705,464 1,215,355 Income tax expense - -

Key Management Personnel Compen

Key Management Personnel Compensation	12 Months Ended
	Jun. 30, 2024
Key Management Personnel Compensation [Abstract]
Key Management Personnel Compensation	Note 6. Key Management Personnel Compensation This note details the nature and amount of remuneration for each Director of Immuron Limited, and for the Key Management Personnel. The Directors of Immuron Limited during the year ended June 30, 2024 were: The following persons held office as Directors of Immuron Limited during the financial year: Dr. Roger Aston, Independent Non-Executive Director (Resigned May 31, 2024) Mr. Paul Brennan, Independent Non-Executive Chairman Mr. Daniel Pollock, Independent Non-Executive Director Mr. Stephen Anastasiou, Independent Non-Executive Director (resigned May 3, 2024) Prof. Ravi Savarirayan, Independent Non-Executive Director Dr. Jeannette Joughin Independent Non-Executive Director (commenced June 1, 2024) The following persons held office as Key Management Personnel of Immuron Limited during the financial year ended June 30, 2024: Mr. Steven Lydeamore, Chief Executive Officer Dr. Jerry Kanellos, Chief Operating Officer Mr. Flavio Palumbo, Chief Commercial Officer The aggregate compensation made to Directors and Other Key Management Personnel of the Company is set out below: 30 June 30 June 30 June A$ A$ A$ Key Management Personnel Compensation Short-term employee benefits 1,637,409 1,394,154 636,673 Post-employment benefits 158,080 5,283 44,489 Long-term benefits 10,607 8,110 15,168 Share-based payment expenses to KMP and their related entities 3,300 200,753 94,890 Total Key Management Personnel Compensation 1,809,396 1,608,300 791,220

Loss per Share

Loss per Share	12 Months Ended
	Jun. 30, 2024
Loss per Share [Abstract]
Loss per Share	Note 7. Loss per Share 30 June 30 June 30 June A$ A$ A$ Basic/Diluted loss per share (in cents) 3.04 1.66 1.25 a) Net loss used in the calculation of basic and diluted loss per share 6,936,957 3,786,507 2,854,254 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 227,860,641 227,798,346 227,579,684 The Company is currently in a loss making position and thus the impact of potential issuance of shares is concluded as anti-dilutive which includes the Company’s options and warrants and performance rights. Treasury shares are excluded from the calculation of weighted average number of ordinary shares.

Financial Assets and Financial

Financial Assets and Financial Liabilities	12 Months Ended
	Jun. 30, 2024
Financial Assets and Financial Liabilities [Abstract]
Financial assets and financial liabilities	Note 8. Financial assets and financial liabilities (a) Cash and cash equivalents 30 June 30 June A$ A$ Cash at Bank and in hand: Cash at bank and in hand 11,657,315 17,159,764 Total 11,657,315 17,159,764 (b) Trade and other receivables 30 June 30 June A$ A$ Current Trade receivables 1 607,436 46,949 Loss allowance (16,233 ) (27,920 ) Accrued income – Australian R&D tax incentive refund 2 768,370 398,391 Other income receivables – R&D grants 3 28,000 - Total 1,387,573 417,420 1 All trade receivables are non-interest bearing. 2 Receivables from the Australian Tax Office in relation to R&D tax incentive refund for the year. 3 The group has recognized $28,000 of EMDG grant in other income receivable for the current financial year (2023: nil (c) Financial assets The group classifies the following as financial assets recognised at fair value through profit or loss (FVPL) as part of Immuron’s strategic investment in Ateria: ● Immuron was entitled to 735,000 share options with a total exercise price of £1,470,000, expiring on 31 July 2023, which Immuron subsequently elected not to exercise; and ● On 22 February 2024 Immuron received 471,306 shares in Ateria upon satisfying performance milestones. Financial assets mandatorily measured at FVPL include the following: 30 June 30 June Notes A$ A$ Current Ateria share options 8(c)(iii) - 221,620 Ateria contingent consideration receivable 8(c)(iii) - 1,612,414 - 1,834,034 (i) Recognized fair value measurements This section explains the judgements and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standards. Recurring fair value measurements Notes Level 2 Level 3 Total $ $ $ At 30 June 2024 Financial assets Ateria share options - - - Ateria contingent consideration receivable - - - Total financial assets - - - Recurring fair value measurements Notes Level 2 Level 3 Total At 30 June 2023 $ $ $ Financial assets Ateria share options 221,620 - 221,620 Ateria contingent consideration receivable - 1,612,414 1,612,414 Total financial assets 221,620 1,612,414 1,834,034 (ii) Amounts recognised in profit or loss During the year, the following losses were recognised in profit or loss: 30 June 30 June 30 June A$ A$ A$ Fair value gains/(losses) to financial assets (557,676 ) (523,666 ) - (iii) Fair value of financial assets The assessed fair value of Ateria share options at acquisition and reporting date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. Reconciliation Level 2 Level 3 Total $ $ $ Financial assets Balance at acquisition date 221,620 1,612,414 1,834,034 Fair value gains/(losses) to financial assets (221,620 ) (336,056 ) (557,676 ) Net foreign exchange gains - 20,595 20,595 Share of loss from associates* - (101,603 ) (101,603 ) Issue of Ateria contingent shares* - (1,195,350 ) (1,195,350 ) Balance at 30 June 2024 - - - * Note: Ateria share options at 30 June 2023 As at 30 June 2023, the fair value of Ateria share options were determined using the following inputs: Value date Expiry date Exercise price No. of Share price Expected Dividend Risk- free Fair value 2023-06-30 2023-07-31 £ 2.00 735,000 £ 1.85 100.00 % 0.00 % 4.18 % £ 0.1583 Ateria contingent consideration receivable at 30 June 2023 As disclosed in Note 10, Ateria contingent consideration receivable was recognized in relation to the acquisition of the interest in Ateria. The assessed fair value of Ateria contingent consideration receivable at acquisition date and reporting date was determined at arm’s length using the last traded share price of £1.85 on 28 February 2023 and the expected number of shares to be received of 457,577. Given positive progress being made in establishing brand identity and sales growth, the most recent capital raising price continues to be the best determination of fair value for Ateria’s shares given that they do not trade on an active market. No reasonably possible changes would result in a material change in value. The number of shares to be received in Ateria is dependent on the financial performance of Ateria. If Ateria achieves a revenue goal for the calendar year 2023 of above £1 million, the number of shares to be received reduces on a linear basis. The shares were received on 22 February 2024. (d) Other current assets 30 June 30 June A$ A$ Prepayments 96,841 158,151 Total 96,841 158,151 (e) Trade and other payables 30 June 30 June Current Trade payables 648,851 790,919 Accrued expenses 1,445,451 394,026 Other payables 41,550 7,824 Total 2,135,852 1,192,769 (f) Deferred income 30 June 30 June Current Deferred grant income - 698,195 Total - 698,195 For the period ended 30 June 2024, the group received $1,901,263 R&D grant from Medical Technology Enterprise Consortium (MTEC) in cash. Refer to Note 3 for further information on income recognized from MTEC during the year.

Non-financial assets and liabil

Non-financial assets and liabilities	12 Months Ended
	Jun. 30, 2024
Non-financial assets and liabilities [Abstract]
Non-financial assets and liabilities	Note 9. Non-financial assets and liabilities (a) Property, plant and equipment Plant and Furniture, Right-of-use Total At 30 June 2022 Cost or fair value 364,856 35,042 229,031 628,929 Accumulated depreciation (345,343 ) (34,905 ) (21,945 ) (402,193 ) Net book amount 19,513 137 207,086 226,736 Year ended 30 June 2023 Opening net book amount 19,513 137 207,086 226,736 Additions 7,067 672 14,320 22,059 Depreciation charge (7,203 ) (131 ) (41,328 ) (48,662 ) Closing net book amount 19,377 678 180,078 200,133 At 30 June 2023 Cost or fair value 371,923 35,714 243,351 650,988 Accumulated depreciation (352,546 ) (35,036 ) (63,273 ) (450,855 ) Net book amount 19,377 678 180,078 200,133 Year ended 30 June 2024 Opening net book amount 19,377 678 180,078 200,133 Additions 195 - - 195 Depreciation charge (5,576 ) (339 ) (40,066 ) (45,981 ) Closing net book amount 13,996 339 140,012 154,347 At 30 June 2024 Cost or fair value 372,118 35,714 243,351 651,183 Accumulated depreciation (358,122 ) (35,375 ) (103,339 ) (496,836 ) Net book amount 13,996 339 140,012 154,347 (b) Inventories 30 June 2024 30 June 2023 Current Non- Total Current Non- Total Raw materials and stores (Colostrum) 139,745 669,285 809,030 - 1,108,256 1,108,256 Work in progress 683,850 683,850 444,905 111,390 556,295 Finished goods (Travelan and Protectyn) 610,020 - 610,020 394,381 - 394,381 Other inventories 150,993 - 150,993 682 - 682 1,584,608 669,285 2,253,893 839,968 1,219,646 2,059,614 (i) Impairment of inventories The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventory, and in particular, the shelf life of inventories that affects obsolescence. Expected shelf-life is reassessed on a regular basis with reference to stability tests which are conducted by an expert engaged by the Company. A comprehensive stability study was completed in August 2020 and the reported findings support a shelf life of at least 130 months for the colostrum drug substance. There were no nil (c) Employee benefit obligations 2024 2023 Current Non- Total Current Non- Total Leave obligations (i) 265,952 8,605 274,557 237,328 1,882 239,210 Performance bonus 256,619 - 256,619 52,080 - 52,080 522,571 8,605 531,176 289,408 1,882 291,290 The current portion of this liability includes all of the accrued annual leave, the unconditional entitlements to long service leave where employees have completed the required period of service and also for those employees that are entitled to pro-rata payments in certain circumstances. Total leave provision of $265,952 (2023: $237,328) is presented as current, since the group does not have an unconditional right to defer settlement for any of these obligations. However, based on past experience, the group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months. (d) Leases (i) Amounts recognized in the balance sheet The balance sheet shows the following amounts relating to leases: 30 June 30 June Right-of-use assets 1 Properties 140,012 180,078 140,012 180,078 Lease liabilities 2 Current 40,556 38,767 Non-current 132,941 150,325 173,497 189,092 1. Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet. 2. Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet. (ii) Amounts recognized in the statement of profit or loss The statement of profit or loss shows the following amounts relating to leases: 2024 2023 Depreciation charge of right-of-use assets Properties 40,066 41,328 40,066 41,328 Interest expense (included in finance cost) 7,576 9,652 Expense relating to short-term leases (included in other expenses) - - Expense relating to leases of low-value assets that are not short-term leases (included in other expenses) - - Expense relating to variable lease payments not included in lease liabilities (included in other expenses) - - Cash paid for principal payments 47,293 35,015 The total finance cash outflow for leases in 2024 was $7,576. The total finance cash outflow for leases in 2023 was $9,652. (iii) The group’s leasing activities and how these are accounted for In November 2021, the group entered into a three-year commercial lease modification for office facilities in Blackburn North. This lease modification is effective from 1 January 2022 and includes an extension option for a further 3 years by written request to the landlord before 31 December 2024. There is no variability and no covenants included in the lease.

Interests in Other Entities

Interests in Other Entities	12 Months Ended
	Jun. 30, 2024
Interests in Other Entities [Abstract]
Interests in other entities	Note 10. Interests in other entities (a) Material subsidiaries The Company’s subsidiaries at 30 June 2024 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights held by the Company. The country of incorporation or registration is also their principal place of business. Percentage of Country of 30 June 30 June Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 100 % (b) Interests in associates Immuron acquired 17.5% interest in Ateria Health Limited (Ateria) on 25 November 2022 with cash consideration. Ateria is a U.K. based company that has developed ground-breaking product for the treatment of irritable bowel syndrome (IBS). The strategic investment advances Immuron’s objective to enter the broader IBS market with leading products and strengthen the distribution of Immuron’s Travelan® products through B2C online platforms and pharmacy and retail channels (B2B) in target markets. Ateria has the same financial year end date of 30 June as that of Immuron. On 22 February 2024, Immuron received 471,306 shares in Ateria upon satisfying performance milestones. This increased Immuron’s interest in Ateria to 23.6%. Steve Lydeamore resigned from the Ateria Board of Directors on 1 May 2024.’ Impairment In 2024, it became clear that Ateria was under significant financial difficulty. In 2024, the impairment loss of $1,456,019 represented the write-down of the Companyʼs investment in Ateria. This was recognised in the statement of profit and loss as Share of loss from associates. The recoverable amount of $0 as at 30 June 2024 was based on value in use. In determining the value in use for the investment, a discounted cash flow (DCF) model and Terminal Value valuation was used. As the current full year EBITDA is negative, no positive value can be attributed to the investment in Ateria using a DCF model. A DCF model plus Terminal Value with a positive valuation requires evidence of Ateriaʼs ability to turn the business around from loss to profit. The Company determined it has insufficent evidence of Ateria’s ability to achieve profitability and therefore determined to impair the investment in full. Name of entity Place of business/ country of incorporation Ownership interest held by the group 2024 2023 Ateria Health Limited United Kingdom 23.6 17.5 (i) Summarised financial information for associates 30 June 30 June The group’s share of loss for the period (1,456,019 ) (324,340 ) Recognised in: Note 30 June 30 June Share of loss for the period - 23.6% (2023: 17.5%) (291,711 ) (324,340 ) Impairment of investment in associate 8(c)(i) (1,164,308 ) (1,456,019 ) (324,340 ) Reconciliation of the consolidated entity’s carrying amount 2024 2023 Opening carrying amount 159,066 - Initial Investment in Ateria Health Limited - 404,117 Acquisition of shares (Note 8(c) (iii)) 1,195,350 79,289 Share of loss in Ateria for the period (190,108 ) (324,340 ) Impairment of investment in Ateria (1,164,308 ) - - 159,066

Company Details

Company Details	12 Months Ended
	Jun. 30, 2024
Company Details [Abstract]
Company Details	Note 11. Company Details The registered office of the Company is: Level 3, 62 Lygon Street, Carlton, Victoria, Australia 3053. The principal place of business of the Company is: Unit 10, 25-37 Chapman Street, Blackburn, Victoria, Australia 3130.

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	12 Months Ended
	Jun. 30, 2024
Contingent Liabilities and Commitments [Abstract]
Contingent liabilities and Commitments	Note 12. Contingent liabilities and Commitments The group had no nil

Share Capital

Share Capital	12 Months Ended
	Jun. 30, 2024
Share Capital [Abstract]
Share capital	Note 13. Share capital 2024 2023 2022 2024 2023 2022 Ordinary shares Fully paid 227,998,346 227,798,346 227,798,346 88,504,043 88,436,263 88,436,263 227,998,346 227,798,346 227,798,346 88,504,043 88,436,263 88,436,263 (i) Movements in ordinary shares: Details Number of Total Balance at 30 June 2021 227,246,596 88,361,303 Issue at $0.12 under ESOP Plan (2021-11-05) 333,000 39,960 Issue at $0.16 in lieu of payment for services (2021-12-17) 218,750 35,000 Less: Transaction costs arising on share issues - - Balance at 30 June 2022 227,798,346 88,436,263 Less: Transaction costs arising on share issues - - Balance at 30 June 2023 227,798,346 88,436,263 Issue at $0.12 on exercise of unlisted options (2024-03-12) 200,000 67,780 Balance at 30 June 2024 227,998,346 88,504,043 (ii) Ordinary shares Ordinary shares entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. Ordinary shares have no par value and the Company does not have a limited amount of authorized capital. (iii) Options Information relating to options, including details of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set out in notes 14 and 17.

Other Reserves

Other Reserves	12 Months Ended
	Jun. 30, 2024
Other Reserves [Abstract]
Other reserves	Note 14. Other reserves The following table shows a breakdown of the consolidated statement of financial position line item ‘other reserves’ and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table. Notes Share-based Foreign Total other At 1 July 2021 3,360,128 106,514 3,466,642 Currency translation differences - 6,708 6,708 Other comprehensive income - 6,708 6,708 Transactions with owners in their capacity as owners Options and warrants issued/expensed 14(ii) 54,930 - 54,930 Options and warrants lapsed/expired 14(ii) (361,861 ) - (361,861 ) At 30 June 2022 3,053,197 113,222 3,166,419 Notes Share-based Foreign Total other At 1 July 2022 3,053,197 113,222 3,166,419 Currency translation differences - (1,012 ) (1,012 ) Other comprehensive income - (1,012 ) (1,012 ) Transactions with owners in their capacity as owners Options and warrants issued/expensed 14(ii) 104,753 - 104,753 Options and warrants lapsed/expired 14(ii) (156,392 ) - (156,392 ) Performance rights issued/expensed 14(ii) 122,201 - 122,201 At 30 June 2023 3,123,759 112,210 3,235,969 Notes Share-based Foreign Total other At 1 July 2023 3,123,759 112,210 3,235,969 Currency translation differences - 2,266 2,266 Other comprehensive income - 2,266 2,266 Transactions with owners in their capacity as owners Options and warrants exercised 14(ii) (43,780 ) - (43,780 ) Options issued in the period (net of adjustments) 14(ii) (11,932 ) - (11,932 ) Lapse of unexercised options 14(ii) (23,957 ) - (23,957 ) Unlisted options issued/expensed 14(ii) 15,231 - 15,231 At 30 June 2024 3,059,321 114,476 3,173,797 (i) Nature and purpose of other reserves Share-based payments The share-based payment reserve records items recognized as expenses on valuation of share options and warrants issued to key management personnel, other employees and eligible contractors. Foreign currency translation Exchange differences arising on translation of foreign controlled entities are recognized in other comprehensive income as described in note 1(d) and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. (ii) Movements in options/warrants and performance rights: Details Notes Number of Total Balance at 30 June 2021 45,309,478 3,360,128 Lapse of unexercised options at $0.50 (2021-07-01) (1,200,000 ) (188,400 ) Issue of ESOP unlisted options at $0.25 (2021-11-05) 1 500,000 18,624 Lapse of unexercised options at $1.94 (2021-11-30) (14,493 ) (28,813 ) Lapse of unexercised options at $1.94 (2022-06-14) (24,721,108 ) (144,648 ) ESOP unlisted options granted at $0.12 (2022-06-27) 1 - 36,306 Balance at 30 June 2022 19,873,877 3,053,197 Share-based payment expenses – options 1 1,430,000 104,753 Lapse of unexercised options (8,424,157 ) (156,392 ) Share-based payment expenses - performance rights 2 - 122,201 Balance at 30 June 2023 12,879,720 3,123,759 Exercise of unlisted options at $0.12 (2024-03-12) (200,000 ) (43,780 ) Performance rights issued 2 1,688,839 0 Lapse of unexercised options (173,600 ) (23,957 ) Unlisted Options Issued/Expensed - 15,231 Options issued in the period (net of adjustments) 3 1,000,000 (11,932 ) Balance at 30 June 2024 15,194,959 3,059,321 1. During the fiscal year 2022, a total of 2,930,000 options were granted to key management personnel. 500,000, 1,000,000 and 1,430,000 options were granted under OIP to Dr. Jerry Kanellos on 26 October 2021, Mr. Paul Brennan on 16 March 2022 and Mr. Steven Lydeamore on 27 June 2022, respectively. 1,430,000 options have been issued to Mr. Steven Lydeamore in July 2022. 1,000,000 options granted to Mr. Brennan upon his appointment are subject to shareholders’ approval after the current reporting period. 2. During the fiscal year 2023, performance rights with a total value of $122,201 were granted to key management personnel and staff as part of their performance bonus. 1,688,839 performance rights were subsequently issued after the reporting period, on 12 July 2023. In which, 1,147,083 and 179,664 performance rights were issued to Mr. Steven Lydeamore and Dr. Jerry Kanellos as part of their fiscal year 2023 performance bonus of $83,000 and $13,000, respectively. These performance rights have nil exercise price, exercisable on issue and expiring on 12 July 2027. 3. 1,000,000 options were granted to Mr. Paul Brennan upon his appointment March 16, 2022, but were subject to shareholder approval that was not obtained until 2023. The options have been expensed over the vesting period from when the service period commenced and Immuron have revised the estimate of the fair value at the grant date. Of the $(11,932) adjustment, $(12,896) relates to the difference between the estimated fair value and the grant date fair value of these options. The fair value at the shareholder approval date was determined using the Black-Scholes option pricing model and takes into account the exercise price, the term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, risk-free interest rate for the term of the security and certain probability assumptions. The offsetting $965 relates to options issued for Dr. Jeannette Joughin.

Segment Reporting

Segment Reporting	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Reporting	Note 15. Segment Reporting Description of segments and principal activities The group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources. The executive management uses the measure of profit and loss to assess segment performance. Management considers the business from both a product and a geographic perspective and has identified two reportable segments: Research and development (R&D): income and expenses directly attributable to the group’s R&D projects performed in Australia and United States. Hyper-immune products: income and expenses directly attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world. Financial breakdown The segment information for the reportable segments for the year ended June 30, 2024 is as follows: Research Hyper-immune Corporate Total 2024 A$ A$ A$ A$ Hyper-immune products revenue - 4,902,865 - 4,902,865 Cost of sales of goods - (1,566,068 ) - (1,566,068 ) Gross profit - 3,336,797 - 3,336,797 Other income 3,364,439 43,760 - 3,408,199 Fair value gains/(losses)to financial assets - - (557,676 ) (557,676 ) Net foreign exchange gains/(losses) - - (27,603 ) (27,603 ) Movement in inventory provision - - - - General and administrative expenses (460,251 ) (3,565 ) (4,091,910 ) (4,555,726 ) Research and development expenses (5,375,461 ) - - (5,375,461 ) Selling and marketing expenses - (2,029,648 ) - (2,029,648 ) Operating profit/(loss) (2,471,273 ) 1,347,344 (4,667,184 ) (5,801,118 ) Finance income - - 327,756 327,756 Finance costs - - (7,576 ) (7,576 ) Share of loss from associates - - (1,456,019 ) (1,456,019 ) Income tax expense - - - - Profit/(loss) for the year (2,471,273 ) 1,347,344 (5,813,028 ) (6,936,957 ) Assets Segment assets 768,370 2,845,096 11,936,503 15,549,969 Total assets 768,370 2,845,096 11,936,503 15,549,969 Liabilities Segment liabilities 604,018 206,524 2,029,983 2,840,525 Total liabilities 604,018 206,524 2,029,983 2,840,525 The segment information for the reportable segments for the year ended June 30, 2023 is as follows: Research Hyper-immune Corporate Total 2023 A$ A$ A$ A$ Hyper-immune products revenue - 1,804,705 - 1,804,705 Cost of sales of goods - (495,558 ) - (495,558 ) Gross profit - 1,309,147 - 1,309,147 Other income 2,551,813 39,685 - 2,591,498 Fair value gains/(losses)to financial assets - - (523,666 ) (523,666 ) Net foreign exchange gains/(losses) - - 363,724 363,724 Movement in inventory provision - 430,932 - 430,932 General and administrative expenses (460,251 ) 26,256 (3,786,910 ) (4,220,905 ) Research and development expenses (2,592,145 ) - - (2,592,145 ) Selling and marketing expenses - (927,423 ) - (927,423 ) Operating profit/(loss) (500,583 ) 878,597 (3,946,852 ) (3,568,838 ) Finance income - - 116,323 116,323 Finance costs - - (9,652 ) (9,652 ) Share of loss from associates - - (324,340 ) (324,340 ) Income tax expense - - - - Profit/(loss) for the year (500,583 ) 878,597 (4,164,521 ) (3,786,507 ) Assets Segment assets 398,391 2,078,643 19,511,148 21,988,182 Total assets 398,391 2,078,643 19,511,148 21,988,182 Liabilities Segment liabilities 604,018 206,524 1,560,804 2,371,346 Total liabilities 604,018 206,524 1,560,804 2,371,346 The segment information for the reportable segments for the year ended June 30, 2022 is as follows: Research Hyper-immune Corporate Total 2022 A$ A$ A$ A$ Hyper-immune products revenue - 765,193 - 765,193 Cost of sales of goods - (241,691 ) - (241,691 ) Gross profit - 523,502 - 523,502 Other income 933,140 24,585 - 957,725 Net foreign exchange gains/(losses) - - 247,558 247,558 General and administrative expenses - (164,087 ) (3,360,301 ) (3,524,388 ) Research and development expenses (657,715 ) - - (657,715 ) Selling and marketing expenses - (416,537 ) - (416,537 ) Operating profit/(loss) 275,425 (32,537 ) (3,112,743 ) (2,869,855 ) Finance income - - 21,785 21,785 Finance costs - - (6,184 ) (6,184 ) Profit/(loss) for the year 275,425 (32,537 ) (3,097,142 ) (2,854,254 ) Assets Segment assets 257,500 1,688,910 22,909,414 24,855,824 Total assets 257,500 1,688,910 22,909,414 24,855,824 Liabilities Segment liabilities 7,053 150,151 1,521,219 1,678,423 Total liabilities 7,053 150,151 1,521,219 1,678,423 Information on geographical regions: The group derives revenue from the transfer of hyper-immune products at a point in time in the following major product lines and geographical regions: Travelan Protectyn Australia United States Canada Australia Total 2024 A$ A$ A$ A$ A$ Hyper-immune products revenue 3,702,876 1,075,614 80,888 43,487 4,902,865 Revenue from external customers 3,702,876 1,075,614 80,888 43,487 4,902,865 Travelan Protectyn Australia United States Canada Australia Total 2023 A$ A$ A$ A$ A$ Hyper-immune products revenue 1,100,725 642,819 1,201 59,960 1,804,705 Revenue from external customers 1,100,725 642,819 1,201 59,960 1,804,705 Travelan Protectyn Australia United States Canada Australia Total 2022 A$ A$ A$ A$ A$ Hyper-immune products revenue 143,378 501,228 63,172 57,415 765,193 Revenue from external customers 143,378 501,228 63,172 57,415 765,193 Information on major customers: During the years ended June 30, 2024, 2023 and 2022, the Company had the following major customers in the hyper-immune product segment with revenues amounting to 10 percent or more of total group revenues: 2024 2023 2022 Customer A 2,308,425 626,107 99,792 Customer B 957,076 - - Customer C 842,173 223,504 34,020 Customer D 552,509 236,437 - Customer E - 465,614 253,803 Customer F - - 263,137 4,660,183 1,551,662 650,752

Cash Flow Information

Cash Flow Information	12 Months Ended
	Jun. 30, 2024
Cash Flow Information [Abstract]
Cash Flow Information	Note 16. Cash Flow Information (a) Reconciliation of cash flow from operations with loss after income tax 30 June 30 June 30 June Net Loss for the Year (6,936,957 ) (3,786,507 ) (2,854,254 ) Adjustments for Depreciation expense 45,981 48,662 26,613 Lease modification - - 15,993 Distribution costs - - 35,000 Expected credit losses (11,687 ) 19,111 8,809 Finance costs 7,576 9,652 6,184 Finance income (327,756 ) (116,323 ) (21,785 ) Share of loss from associates 1,456,019 Leave provision expense 44,863 27,235 45,470 Share-based payment expenses 3,299 226,954 94,890 Unrealized net foreign currency gains (76,771 ) (422,881 ) (234,793 ) Change in operating assets and liabilities: Add decrease in trade and other receivables (958,466 ) 226,365 (336,998 ) Add (increase) / decrease in inventories (194,279 ) (776,100 ) 275,605 Add (increase) / decrease in other operating assets 71,353 414,249 (494,143 ) Add (increase) / decrease in financial assets 557,676 848,006 Add (decrease) / increase in trade and other payables 890,102 31,876 285,616 Add (decrease) / increase in other operating liabilities (451,092 ) 654,506 - (5,880,139 ) (2,595,195 ) (3,147,793 ) (b) Non-cash financing and investing activities See Note 17 for details regarding issues of options to employees.

Share-Based Payments

Share-Based Payments	12 Months Ended
	Jun. 30, 2024
Notes and other explanatory information [abstract]
Share-based Payments	Note 17. Share-based Payments a) Executive share and option plan The establishment of the Omnibus Incentive Plan (OIP) was approved by shareholders at the 2021 annual general meeting. The plan is designed to provide long-term incentives for executives (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board’s discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits. Set out below are summaries of all listed and unlisted options, including those issued under OIP: 2024 2023 2022 Average Number of Average Number of options Average Number of As at 1 July 0.27 12,879,720 0.37 19,873,877 0.31 45,309,478 Granted during the year 0.19 2,000,000 0.12 1,430,000 0.25 500,000 Exercised during the year 0.12 (200,000 ) - - - - Forfeited/lapsed during the year 0.18 (173,600 ) 0.48 (8,424,157 ) 0.27 (25,935,601 ) As at 30 June 0.26 14,506,120 0.27 12,879,720 0.37 19,873,877 Vested and exercisable at 30 June 0.27 13,346,386 0.27 12,610,802 0.37 19,538,877 Share options outstanding at the end of the year have the following expiry date and exercise prices: Exercise Share Share Share Grant date Expiry (A$ unless 30 June 30 June 30 June 2018-03-15 2023-03-15 0.468 - - 7,897,647 2017-06-09 (warrants) 2022-06-08 USD 0.3125 - - - 2018-03-15 2023-03-15 0.585 - - 526,510 2019-05-23 (warrants) 2024-05-23 USD 0.125 - 173,600 173,600 2019-07-16 (warrants) 2024-07-16 USD 0.125 116,120 116,120 116,120 2018-07-13 2021-07-01 0.500 - - - 2019-11-06 2024-02-10 0.500 - - - 2020-10-29 2024-04-14 0.12 7,900,000 8,100,000 8,100,000 2020-07-24 (warrants) 2025-07-21 USD 0.5859 2,560,000 2,560,000 2,560,000 2021-10-26 2025-10-26 0.25 500,000 500,000 500,000 2022-06-27 2026-06-27 0.12 1,430,000 1,430,000 - 2023-11-21 2027-11-21 0.25 1,000,000 - - 2024-06-19 2028-06-19 0.13 1,000,000 - - Total 14,506,120 12,879,720 19,873,877 Weighted average remaining contractual life of options outstanding at end of period 2.01 1.35 1.54 (i) Fair value of options granted The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions. The model inputs for options granted under OIP during the year ended June 30, 2024 included: Share price Fair value Exercise at grant Risk- free date per price No. of date Expected Dividend interest option Grant date Expiry date (A$) options (A$) volatility yield rate (A$) 2023-11-21 2027-11-21 0.25 1,000,000 0.08 119.21 % 0.00 % 4.09 % 0.0511 2024-06-19 2028-06-19 0.13 1,000,000 * 0.09 90.42 % 0.00 % 3.97 % 0.0524 2,000,000 * 1,000,000 options granted to Dr. Jeannette Joughin are subject to shareholder approval at the upcoming AGM on 26 November 2024. No The model inputs for options granted under OIP during the year ended June 30, 2022 included: Share price Fair value Exercise at grant Risk- free date per price No. of date Expected Dividend interest option Grant date Expiry date (A$) options (A$) volatility yield rate (A$) 2021-10-26 2025-10-26 0.25 500,000 0.12 131.70 % 0.00 % 0.69 % 0.0886 2022-06-27 2026-06-27 0.12 1,430,000 * 0.07 128.10 % 0.00 % 3.31 % 0.0530 2022-03-15 2026-06-27 0.12 1,000,000 * 0.07 128.10 % 0.00 % 3.31 % 0.0530 2,930,000 * 1,430,000 options granted to Mr. Steven Lydeamore on 27 June 2022 and subsequently issued after the reporting period, on 1 July 2022. 1,000,000 options granted to Mr. Paul Brennan on 15 March 2022. The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. b) Expenses arising from share-based payment transactions Total expenses arising from share-based payment transactions recognized during the period were as follows: 2024 2023 2022 Options issued under OIP 3,299 104,753 54,930 Shares issued under OIP - - 39,960 Performance rights issued under OIP 1 - 122,201 - 3,299 226,954 94,890 1 It was agreed that performance bonus for selected employees for the year ended 30 June 2023 would be paid in performance rights rather than cash. Performance rights to be issued to employees are long-term incentives under OIP.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 18. Related Party Transactions (a) Subsidiaries and associates Interests in subsidiaries and associates are set out in note 10(a) and 10(b), respectively. (b) Transactions with other related parties The following transactions occurred with related parties: 2024 2023 2022 Amounts settled in cash or shares for goods and services Purchases of various goods and services from entities controlled by key management personnel (i) 102,293 99,667 154,364 Legal services by key management personnel (ii) - - 20,000 Other (iii) 17,325 17,065 - (i) Purchases from entities controlled by key management personnel The group acquired the following goods and services from entities that are controlled by members of the group’s key management personnel: ● rental of an office suite (Wattle Laboratories Pty Ltd); and Effective January 2016, we executed a Lease Agreement with Wattle Laboratories Pty Ltd, (“Wattle”), an entity part-owned and operated by our non- executive director, Mr. Stephen Anastasiou (resigned May 3, 2024), whereby we lease part of their Blackburn office facilities for our operations at a rental rate of A$38,940 per year, payable in monthly installments. The rental agreement is subject to annual rental increases. The lease was recently renewed for a three-year term commencing January 1, 2019 with an additional three-year option period. This lease was extended on January 1, 2022 including an extension option for a further 3 years by written request to the landlord before December 31, 2024. The lease may be terminated by either party upon six months’ written notice. During the fiscal years ended June 30, 2022, 2023 and 2024, we paid Wattle A$42,364, A$44,667 and A$47,293 (excluding Goods and Services Tax), respectively. ● warehousing, distribution and invoicing services (Grandlodge Capital Pty Ltd or “Grandlodge”). Commenced on June 1, 2013, Grandlodge provides warehousing, distribution and invoicing services for our products for A$70,000 per year. The terms of the agreement were to have fees payable in new fully paid ordinary shares in Immuron Limited as a set price of A$0.16 per share. Grandlodge was contracted on commercial terms in annual agreements commenced on July 1, 2020 and 2021 to provide warehousing, distribution and invoicing services for Immuron’s products for A$70,000 and A$77,000 per annum, respectively. The terms of the agreement were to have fees payable in cash. Furthermore, in fiscal 2022 an additional A$35,000 was recognized and paid in shares to Grandlodge as per the shareholders’ approval at the AGM held on December 15, 2021. A new annual agreement commenced on July 1, 2022. Grandlodge was contracted on commercial terms to provide warehousing, distribution and invoicing services for Immuron’s products for A$55,000 per annum. Grandlodge is reimbursed in cash for all reasonable costs and expenses incurred in accordance with their scope of works under the oral agreement, unless both Grandlodge and we agree to an alternative method of payment. The oral agreement may be terminated by either party upon providing the other party with 30 days written notice of the termination of the agreement. Aggregate amounts of each of the above types of other transactions with key management personnel of Immuron Limited: 2024 A$ 2023 A$ 2022 A$ Amounts settled in cash or shares during the period Rental of an office suite from Wattle Laboratories Pty Ltd 47,293 44,667 42,364 Services rendered by Grandlodge Capital Pty Ltd 55,000 55,000 112,000 102,293 99,667 154,364 ii) Legal services by key management personnel Legal services were provided by key management personal during the fiscal year 2022. No legal services were provided by key management personal in fiscal year 2024 or fiscal year 2023. iii) Other During the fiscal year 2023, the group engaged a related party to Chief Operating Officer as a casual staff for monitoring of owned and external online channels for product related questions and pharmacovigilance, which amounted to $17,325 (2023: $17,065) including superannuation. (c) Outstanding balances arising from sales/purchases of goods and services The following balances are outstanding at the end of the reporting period in relation to transactions with related parties: 2024 A$ 2023 A$ 2022 A$ Current payables (purchases of goods and services) Entities controlled by key management personnel 55,000 55,000 77,000

Financial Risk Management Objec

Financial Risk Management Objectives and Policies	12 Months Ended
	Jun. 30, 2024
Financial Risk Management Objectives and Policies [Abstract]
Financial Risk Management Objectives and Policies	Note 19. Financial Risk Management Objectives and Policies This note explains the group’s exposure to financial risks and how these risks could affect the group’s future financial performance. The group’s risk management is predominantly controlled by the Board. The Board monitors the group’s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk. (a) Market risk Foreign exchange risk The group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations. Foreign exchange rate risk arises from financial assets and financial liabilities denominated in a currency that is not the group’s functional currency. Exposure to foreign currency risk may result in the fair value of future cash flows of a financial instrument fluctuating due to the movement in foreign exchange rates of currencies in which the group holds financial instruments which are other than the Australian dollar (AUD) functional currency of the group including United States dollar (USD) and Canadian dollar (CAD). This risk is measured using sensitivity analysis and cash flow forecasting. The cost of hedging at this time outweighs any benefits that may be obtained. Exposure The group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars, was as follows: 2024 2023 USD CAD HKD USD CAD HKD Cash and cash equivalents 2,721,574 13,453 - 4,770,507 14,293 - Trade receivables 36,297 88,459 - 46,821 - - Trade payables 250,865 42,047 18,308 577,644 1,841 24,636 Total exposure 3,008,736 143,959 18,308 5,394,972 16,134 24,636 Sensitivity As shown in the table above, the group is primarily exposed to changes in USD/AUD exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from USD denominated financial instruments. The impact on other components of equity arises from the translation of foreign subsidiary financial statements into AUD. The group has conducted a sensitivity analysis of its exposure to foreign currency risk. The group is currently materially exposed to the United States dollar (USD). The sensitivity analysis is conducted on a currency-by-currency basis using the sensitivity analysis variable, which is based on the average annual movement in exchange rates over the past five years at year-end spot rates. The variable for each currency the group is materially exposed to is listed below: ● USD: 4.8% (2023: 5.8%) Impact on loss for Impact on other 2024 2023 2024 2023 USD/AUD exchange rate – change by 4.8% (2023: 5.8%) 144,419 312,908 5,495 37 * Holding all other variables constant Loss is more sensitive to movements in the AUD/USD exchange rates in 2024 than 2023 because of the increased amount of USD denominated cash and cash equivalents and the increased variability of the AUD/USD exchange rate. Equity is less sensitive to movements in the AUD/USD exchange rates in 2024 than 2023 because of the decreased size of the foreign currency translation reserve for the subsidiary with USD functional currency. The group’s exposure to other foreign exchange movements is not material. (b) Credit risk Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the group. (i) Risk management Credit risk is managed through the maintenance of procedures (such as the utilization of systems for the approval, granting and renewal of credit limits, regular monitoring of exposures against such limits and monitoring the financial stability of significant customers and counterparties), ensuring to the extent possible that customers and counterparties to transactions are of sound credit worthiness. Such monitoring is used in assessing receivables for impairment. Credit terms are normally 30 days from the invoice date. Risk is also minimized through investing surplus funds in financial institutions that maintain a high credit rating. (ii) Security For some trade receivables the group may obtain security in the form of guarantees, deeds of undertaking or letters of credit which can be called upon if the counterparty is in default under the terms of the agreement. (iii) Impairment of financial assets The group has one type of financial asset subject to the expected credit loss model: ● trade receivables for sales of inventory While cash and cash equivalents are also subject to the impairment requirements of AASB 9, the identified impairment loss was immaterial. Trade receivables The group applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 60 months before June 30, 2024 and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. On that basis, the loss allowance as at June 30, 2024 was determined as follows for trade receivables: Days past due 30 June 2024 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 1 0.23 % 1.80 % 0.00 % 5.83 % 16.15 % 50.90 % - Gross carrying amount 1 463,334 75,725 8,458 4,183 42,631 13,105 607,436 Loss allowance 1,073 1,361 - 244 6,885 6,670 16,233 1. Trade receivables balance of $607,436 represents 12.39% of $4,902,865 revenue from contracts with customers of the current fiscal year. Based on the expected credit losses assessment and review of individual accounts, $16,233 was provided for. Subsequent to 30 June 2024, above 90% of the trade receivables balance has since been received in cash. On that basis, the loss allowance as at June 30, 2023 was determined as follows for trade receivables: Days past due 30 June 2023 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 1 59.42 % 0.00 % 61.57 % 66.75 % 0.00 % 0.00 % Gross carrying amount 1 44,345 - 3,294 (690 ) - - 46,949 Loss allowance 26,352 - 2,028 (460 ) - - 27,920 1. Trade receivables balance of $46,949 represents 2.6% of $1,804,705 revenue from contracts with customers of the current fiscal year. Based on the expected credit losses assessment and review of individual accounts, $27,920 was provided for. Subsequent to 30 June 2023, above 90% of the trade receivables balance has since been received in cash. Trade receivables are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater than 121 days past due. Impairment losses on trade receivables are presented as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same line item. (c) Liquidity risk Liquidity risk arises from the possibility that the group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The group manages this risk through the following mechanisms: ● preparing forward looking cash flow analyses in relation to its operating, investing and financing activities; ● obtaining funding from a variety of sources; ● maintaining a reputable credit profile; ● managing credit risk related to financial assets; ● investing cash and cash equivalents and deposits at call with major financial institutions; and ● comparing the maturity profile of financial liabilities with the realisation profile of financial assets. Maturities of financial liabilities The tables below analyze the group’s financial liabilities into relevant maturity groupings based on their contractual maturities. The amounts disclosed in the table are the contractual discounted cash flows. Contractual maturities Less than 6 - 12 Between Between Over Total Carrying of financial liabilities A$ A$ A$ A$ A$ A$ A$ At 30 June 2024 Trade and other payables 648,851 - - - - 648,851 648,851 Lease liabilities 20,278 20,278 46,342 86,598 - 173,497 173,497 Total 664,129 20,278 46,343 86,598 - 822,348 822,348 At 30 June 2023 Trade and other payables 798,743 - - - - 798,743 798,743 Lease liabilities 19,165 19,602 40,556 109,769 - 189,092 189,092 Total 817,908 19,602 40,556 109,769 - 987,835 987,835

Events Occurring After the Repo

Events Occurring After the Reporting Date	12 Months Ended
	Jun. 30, 2024
Events Occurring After the Reporting Date [Abstract]
Events occurring after the Reporting Date	Note 20. Events occurring after the Reporting Date On 3 July 2024, the Company lodged the SEC Form F-3 registration statement and secured the At-the-Market (ATM) funding facility with H.C. Wainright & Co., LLC with access of up to approximately US$2m funding. No other matter or circumstance has occurred subsequent to period end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial years.

Parent Entity Financial Informa

Parent Entity Financial Information	12 Months Ended
	Jun. 30, 2024
Parent Entity Financial Information [Abstract]
Parent entity financial information	Note 21. Parent entity financial information The individual financial statements for the parent entity show the following aggregate amounts: 2024 2023 Balance sheet Current assets 14,724,947 20,348,996 Non-current assets 859,110 1,580,065 Total assets 15,584,057 21,929,061 Current liabilities 2,775,925 2,213,981 Non-current liabilities 141,510 152,207 Total liabilities 2,917,435 2,366,188 Shareholders’ equity Share capital 88,504,043 88,436,263 Reserves - - Share-based payments 3,059,321 3,123,759 Accumulated losses (78,896,742 ) (71,997,149 ) 12,666,662 19,562,873 Loss for the year 6,899,593 3,700,827 Total comprehensive loss 6,899,593 3,700,827 (b) Guarantees entered into by the parent entity The parent entity has not nil (c) Contingent liabilities of the parent entity The parent entity did not (d) Contractual commitments for the acquisition of property, plant or equipment The parent entity has not nil (e) Determining the parent entity financial information The financial information for the parent entity has been prepared on the same basis as the consolidated financial statements, except as set out below. (i) Investments in subsidiaries Investments in subsidiaries are accounted for at cost in the financial statements of Immuron Limited. (ii) Intercompany loan Total comprehensive loss of the parent entity includes the fully impaired intercompany loan.

Auditors' Remuneration

Auditors' Remuneration	12 Months Ended
	Jun. 30, 2024
Auditors Remuneration [Abstract]
Auditors' Remuneration	Note 22. Auditors’ Remuneration The following table sets forth, for each of the years indicated, the fees billed by Grant Thornton Audit Pty Ltd. (i) Audit services Year Ended 2024 2023 Audit and review of financial statements 1 254,350 241,583 254,350 241,583 1 Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide. (ii) All other fees Year Ended 2024 2023 EMDG grant consulting services 7,210 3,000 7,210 3,000 Australian Disclosure Requirements All press releases, financial reports and other information are available using the stock code IMC on the Australian Stock Exchange website: www2.asx.com.au. Consolidated Entity Disclosure Statement: Name of entity Type of entity Trustee, partner, or participant in joint venture % of share capital held Country of incorporation Australian resident or foreign resident (for tax purpose) Foreign tax jurisdiction(s) of foreign residents Immuron Limited Body corporate n/a n/a Australia Australian n/a Immuron Inc. Body corporate n/a 100 United States Foreign United States Immuron Canada Ltd Body corporate n/a 100 Canada Foreign Canada Anadis ESP Pty Ltd Body corporate n/a 100 Australia Australian n/a BASIS OF PREPARATION This consolidated entity disclosure statement (CEDS) has been prepared in accordance with the Corporations Act 2001 and includes information for each entity that was part of the consolidated entity as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements. DETERMINATION OF TAX RESIDENCY Section 295 (A)(vi) of the Corporation Act 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as there are different interpretations that could be adopted and which could give rise to a different conclusion on residency. In determining tax residency, the Group has applied the following interpretations: Australian tax residency The Group has applied current legislation and judicial precedent, including having regard to the Tax Commissioner’s public guidance in Tax Ruling TR 2018/5. Foreign tax residency Where necessary, the Group has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable foreign tax legislation has been complied with (see section 295(3A)(vii) of the Corporations Act 2001). Australian Disclosure Requirements Directors’ Declaration In the directors’ opinion: (a) the financial statements and Notes set out on pages F-1 to F-46 are in accordance with the Corporations Act 2001, including: (i) Complying with Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements, and (ii) Giving a true and fair view of the consolidated entity’s financial position as at June 30, 2024 and of its performance for the fiscal year ended on that date, and (b) There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable. (c) The consolidated entity disclosure statement is true and correct at 30 June 2024. Note 1 ‘Basis of preparation’ confirms that the financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board. The directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the Corporations Act 2001. This declaration is made in accordance with a resolution of the directors.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of preparation	(a) Basis of preparation These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board and the Corporations Act 2001 (i) Compliance with IFRS The consolidated financial statements of the Immuron Limited group also comply with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). (ii) Historical cost convention The financial statements have been prepared on a historical cost basis. (iii) Going concern The group is in a position to meet future commitments in the current business cycle and pay its debts as and when they fall due. Furthermore, the group is able to progress its research and development programs for at least the next 12 months. The annual report has been prepared on a going concern basis. Accordingly, the annual report does not include adjustments relating to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the group not continue as a going concern. This note provides a list of the material accounting policies adopted in the preparation of these consolidated financial statements to the extent they have not already been disclosed in the other notes above. These policies have been consistently applied to all the years presented, unless otherwise stated. The financial statements are for the group consisting of Immuron Limited and its subsidiaries. (iv) New standards and interpretations not yet adopted There are no standards that are not yet effective and that would be expected to have a material impact on the Company in the current or future reporting years and on foreseeable future transactions. Summary of material accounting policies The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial report. The accounting policies have been consistently applied, unless otherwise stated.
Principles of consolidation and equity accounting	(b) Principles of consolidation and equity accounting (i) Subsidiaries Subsidiaries are all entities (including structured entities) over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases. The acquisition method of accounting is used to account for business combinations by the group. Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group. (ii) Associates Associates are all entities over which the group has significant influence but not control or joint control. Investments in associates are accounted for using the equity method of accounting (see (iii) below), after initially being recognized at cost. On initial recognition, where an associate meets the definition of a business, AASB 3 Business Combinations applied by analogy. (iii) Equity method Under the equity method, the share of the profits or losses of the associate is recognized in profit or loss and the share of the movements in equity is recognized in other comprehensive income. Investments in associates are carried in the statement of financial position at cost plus post-acquisition changes in the group’s share of net assets of the associate. Goodwill relating to the associate is included in the carrying amount of the investment and is neither amortized nor individually tested for impairment. Dividends received or receivable from associates reduce the carrying amount of the investment. When the group’s share of losses in an associate equal or exceeds its interest in the associate, including any unsecured long-term receivables, the group does not recognize further losses, unless it has incurred obligations or made payments on behalf of the associate. The Group reports impairment losses of associates within the share of loss from associates. (iv) Changes in ownership interests The group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the group. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognized in a separate reserve within equity attributable to owners of Immuron Limited. When the group ceases to consolidate or equity account for an investment because of a loss of control, joint control or significant influence, any retained interest in the entity is remeasured to its fair value with the change in carrying amount recognized in profit or loss. This fair value becomes the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate or financial asset. In addition, any amounts previously recognized in other comprehensive income in respect of that entity are accounted for as if the group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognized in other comprehensive income are reclassified to profit or loss. If the ownership interest in an associate is reduced but joint control or significant influence is retained, only a proportionate share of the amounts previously recognized in other comprehensive income are reclassified to profit or loss where appropriate.
Segment reporting	(c) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. This has been identified as the executive management team consisting of the CEO, COO and CCO. Management considers the business from both a product and a geographic perspective and has identified two reportable segments: Research and development (R&D) and Hyper-immune products. See Note 15 for more details.
Foreign currency translation	(d) Foreign currency translation (i) Functional and presentation currency Items included in the financial statements of each of the group’s entities are measured using the currency of the primary economic environment in which the entity operates (‘the functional currency’). The consolidated financial statements are presented in Australian dollar (“A$” or “$”), which is Immuron Limited’s functional and presentation currency. (ii) Transactions and balances Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss. Foreign exchange gains and losses that relate to borrowings are presented in the consolidated statement of profit or loss and other comprehensive income, within finance costs. All other foreign exchange gains and losses are presented in the consolidated statement of profit or loss and other comprehensive income on a net basis within other gains/(losses). Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. For example, translation differences on non-monetary assets and liabilities such as equities held at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss and translation differences on non-monetary assets such as equities classified as at fair value through other comprehensive income are recognized in other comprehensive income. (iii) Group companies The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows: ● assets and liabilities for each consolidated balance sheet presented are translated at the closing rate at the date of that consolidated balance sheet; ● income and expenses for each consolidated statement of profit or loss and consolidated statement of profit or loss and other comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and ● all resulting exchange differences are recognized in other comprehensive income. On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognized in other comprehensive income. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.
Income and revenue recognition	(e) Income and revenue recognition (i) Sale of hyper-immune products Revenue arises mainly from the sale of hyperimmune products. To determine whether to recognize revenue, the group follows the process of identifying the contract with a customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when performance obligations are satisfied. Revenue from the sale of hyperimmune products is recognized at a point in time when or as the group transfers control of the assets to the customer upon delivery of the products or in the case of consignment sales when the distributor sells the product to the customer. The general standard payments terms for customers are 30 days. There is no significant cost to obtain the contract. However, there is variable consideration due to rebates, discounts and refunds. The variable amount of consideration is allocated entirely to the distinct good that is consistent with the amount of consideration to which the group expects to be entitled in exchange for transferring the promised goods to the customer. The group offers rebates of up to 15% to some loyal customers in Australia. There are no warranties. Returns and refunds are provided where this is outlined in a customer agreement. The group does not have a formal policy in place relating to stock returns. In cases where we have a contract in place with a distributor, and that contract includes a stock return policy, we will adhere to the policy listed in the contract. For all other distributors, stock returns are negotiated on a case-by-case basis. The exception to this is where stock is short dated to within 3 months. In this case we will offer replacement stock or a refund. (ii) Financing components The group does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the group does not adjust any of the transaction prices for the time value of money.
Grants from government and non-government sources	(f) Grants from government and non-government sources Grants are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the group will comply with all attached conditions. Other income amounts are recognized when it has been established that the conditions of the grants have been met and that the expected amount can be reliably measured. Grants are recognized in profit or loss on a systematic basis over the periods in which the Group recognizes as expenses the related costs for which the grants are intended to compensate. (i) Accrued receivables These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive. (ii) Research and development (“R&D”) grants from MTEC The group’s other grant income is recognized when compliance with the conditions attached to the grant have been determined and the group has ascertained the grant will be received and the amount can be reliably measured. For the year ended 30 June 2024, the group has recognized $2,599,458 (2023: $2,158,936) R&D grant from Medical Technology Enterprise Consortium (“MTEC”). These grants are recognized in profit or loss on a systematic basis over the periods in which the Group recognizes as expenses the related costs for which the grants are intended to compensate. (iii) Deferred income Government grants and other grants relating to costs are deferred and recognized in profit or loss over the period necessary to match them with the costs that they are intended to compensate.
Income tax	(g) Income tax The income tax expense or credit for the period is the tax payable on the current period’s taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred tax assets are recognized only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. Current and deferred tax is recognized in profit or loss, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity, respectively. As per IFRIC 23 Uncertainty over Income Tax Treatments, where it is probable, the group has determined tax balances consistently with the tax treatment used or planned to be used in its income tax filings. Where the group has determined that it is not probable that the taxation authority will accept an uncertain tax treatment, the most likely amount or the expected value has been used in determining taxable balances (depending on which method is expected to better predict the resolution of the uncertainty).
Leases	(h) Leases Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments: ● fixed payments (including in-substance fixed payments), less any lease incentives receivable ● variable lease payment that are based on an index or a rate ● amounts expected to be payable by the lessee under residual value guarantees ● the exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and ● payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be determined, or the group’s incremental borrowing rate. Right-of-use assets are measured at cost comprising the following: ● the amount of the initial measurement of lease liability ● any lease payments made at or before the commencement date, less any lease incentives received ● any initial direct costs, and ● restoration costs. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short- term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT-equipment and small items of office furniture.
Business combinations	(i) Business combinations Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognized and also recognizes additional assets and liabilities during the measurement period, based on new information obtained about facts and circumstances that existed at acquisition date. The measurement period ends on either the earlier of (i) 12 months from the date of acquisition or (ii) when the acquirer receives all the information possible to determine fair value. Acquired assets and liabilities are initially recognized at their fair value. Any excess consideration paid is recognized as goodwill. Any excess net assets relative to consideration paid is recognized as a gain or bargain purchase. Consideration paid, including any contingent assets and liabilities acquired, are initially and subsequently measured at fair value. Any changes in fair value of contingent consideration payable or receivable are recognized as gain or loss on the income statement.
Impairment of assets	(j) Impairment of assets An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash- generating units). Non-financial assets that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.
Cash and cash equivalents	(k) Cash and cash equivalents For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the consolidated balance sheet.
Trade receivables	(l) Trade receivables Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less loss allowance. The group applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables assets have been grouped based on shared credit risk characteristics and the days past due. The expected loss rates are based on the payment profiles of sales over a period of 60 months before June 30, 2024 and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. (i) Classification as trade receivables Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognized at fair value. The group holds the trade receivables with the objective of collecting the contractual cash flows and therefore measures them subsequently at amortized cost using the effective interest method. Details about the group’s impairment policies and the calculation of the loss allowance are provided below. (ii) Fair value of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value. (iii) Risk management The Group’s risk management is predominantly controlled by the Board. The Board monitors the Group’s financial risk management policies and exposures and approves substantial financial transactions. It also reviews the effectiveness of internal controls relating to market risk, credit risk and liquidity risk. The Board is responsible for overseeing the establishment and implementation of the risk management system, and reviews and assesses the effectiveness of the Company’s implementation of that system on a regular basis. The Board and Senior Management identify the general areas of risk and their impact on the activities of the Company, with Management performing a regular review of: Ø the major risks that occur within the business; the degree of risk involved; Ø the current approach to managing the risk; and Ø if appropriate, determine: ○ any inadequacies of the current approach; and ○ possible new approaches that more efficiently and effectively address the risk. Management report risks identified to the Board through the monthly Operations Report. The Company seeks to ensure that its exposure to undue risk which is likely to impact its financial performance, continued growth and survival is minimized in a cost effective manner.
Inventories	(m) Inventories (i) Raw materials and stores, work in progress and finished goods Raw materials and stores, work in progress and finished goods are stated at the lower of cost and net realizable value. Cost comprises of direct materials, direct labor and an appropriate proportion of variable and fixed overhead expenditure, the latter being allocated on the basis of normal operating capacity. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.
Investments and other financial assets	(n) Investments and other financial assets (i) Classification The group classifies its financial assets in the following measurement categories: ● those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss); and ● those to be measured at amortized cost. The classification depends on the group’s business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in profit or loss and other comprehensive income. For investments in equity instruments that are not held for trading, this will depend on whether the group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI). (ii) Recognition and derecognition Regular way purchases and sales of financial assets are recognized on trade-date, the date on which the group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the group has transferred substantially all the risks and rewards of ownership. (iii) Measurement At initial recognition, the group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss. (iv) Impairment The group assesses on a forward-looking basis the expected credit losses associated with its debt instruments carried at amortized cost and FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk. For trade receivables, the group applies the simplified approach permitted by AASB 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables. (v) Income recognition - Interest income Interest income is recognized using the effective interest method. When a receivable is impaired, the group reduces the carrying amount to its recoverable amount, being the estimated future cash flow discounted at the original effective interest rate of the instrument, and continues unwinding the discount as interest income. Interest income on impaired loans is recognized using the original effective interest rate.
Property, plant and equipment	(o) Property, plant and equipment Property, plant and equipment is stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Depreciation is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives or, in the case of leasehold improvements and certain leased plant and equipment, the shorter of the useful life of the asset and the term of lease as follows: ● Plant and equipment 2 - 5 years ● Furniture, fittings and equipment 3 - 15 years ● Right-of-use assets 3 years The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss.
Intangible assets	(p) Intangible assets (i) Research and development Expenditure on research activities, undertaken with the prospect of obtaining new scientific or technical knowledge and understanding, is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense when it is incurred. Expenditure on development activities, being the application of research findings or other knowledge to a plan or design for the production of new or substantially improved products or services before the start of commercial production or use, is capitalized if it is probable that the product or service is technically and commercially feasible, will generate probable economic benefits, adequate resources are available to complete development and cost can be measured reliably. Other development expenditure is recognized in the consolidated statement of profit or loss and other comprehensive income as an expense as incurred.
Trade and other payables	(q) Trade and other payables These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.
Employee benefits	(r) Employee benefits (i) Short-term obligations Liabilities for wages and salaries, including non-monetary benefits, annual leave and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognized in respect of employees’ services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet. (ii) Other long-term employee benefit obligations In some countries, the group also has liabilities for long service leave and annual leave that are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. These obligations are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the end of the reporting period of high-quality corporate bonds with terms and currencies that match, as closely as possible, the estimated future cash outflows. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognized in profit or loss. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur. (iii) Share-based payments Share-based compensation benefits are provided to employees via the Omnibus Incentive Plan (OIP). Employee options The fair value of options granted under the OIP is recognized as a share-based payment expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted: - including any market performance conditions (e.g. the company’s share price); - excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the company over a specified time period); and - including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holdings shares for a specific period of time). The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity. The Group also has performance rights that are granted to key management personal and employees. These can be settled in cash or shares at the discretion of the Board. The performance rights are based on non-market key performance indicators (KPIs). They are expensed over the service period based on an estimate of KPIs that are expected to be achieved. Where it is expected that they will be settled in cash, a corresponding liability is recognized.
Contributed equity	(s) Contributed equity Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Loss per share	(t) Loss per share (i) Basic loss per share Basic loss per share is calculated by dividing: ● the loss attributable to owners of the company, excluding any costs of servicing equity other than ordinary shares ● by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year. (ii) Diluted loss per share Diluted loss per share adjusts the figures used in the determination of basic loss per share to take into account: ● the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and ● the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.
Rounding of amounts	(u) Rounding of amounts The company is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the ‘rounding off’ of amounts in the financial statements. Amounts in the financial statements have been rounded off in accordance with the instrument to the nearest dollar.
Goods and services tax (GST)	(v) Goods and services tax (GST) Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognized as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the consolidated balance sheet. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flows.
Parent entity financial information	(w) Parent entity financial information The financial information for the parent entity, Immuron Limited, disclosed in Note 21 has been prepared on the same basis as the consolidated financial statements, except that accounted for at cost in the financial statements of Immuron Limited.
Fair value measurement	(x) Fair value measurement (i) Fair value hierarchy This section explains the judgements and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels prescribed under the accounting standards. There were no transfers between different levels for recurring fair value measurements during the period. The group’s policy is to recognize transfers into and out of fair value hierarchy levels as at the end of the reporting period. Level 1: Level 2: Level 3: (ii) Valuation techniques used to determine fair values Specific valuation techniques used to value financial instruments include: ● the use of commercial market prices ● the expected number of shares to be received ● for share options - option pricing models (e.g. Black-Scholes model)

Revenue and Other Income (Table

Revenue and Other Income (Tables)	12 Months Ended
	Jun. 30, 2024
Revenue and Other Income [Abstract]
Schedule of Revenue and Other Income	30 June 30 June 30 June Notes A$ A$ A$ Revenue Revenue from Operating Activities Revenue from contracts with customers at a point in time 4,902,865 1,804,705 765,193 Total Revenue from Operating Activities 4,902,865 1,804,705 765,193 Grant Income Australian R&D tax incentive refund 764,981 392,877 257,500 MTEC R&D grant 2,599,458 2,158,936 369,045 HJF R&D grant - - 306,595 EMDG grant 28,000 28,000 - Other income 15,760 11,685 24,585 Total Grant Income 3,408,199 2,591,498 957,725 Other Gains/(Losses) – Net Fair value gains/(losses) to financial assets 8 (c)(ii) (557,676 ) (523,666 ) - Net foreign exchange gains/(losses) (27,603 ) 363,724 247,558 Movement in inventory provision - 430,932 -

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2024
Expense [Abstract]
Schedule of Expenses	30 June 30 June 30 June 2024 2023 2022 General and administrative expenses Accounting and audit 576,540 657,970 499,331 Bad debts - 2,376 - Consulting 120,851 23,241 226,710 Depreciation 45,981 48,662 42,606 Employee benefits 2,353,625 1,874,963 1,212,721 Expected credit losses (11,687 ) 19,111 8,809 Insurance 321,679 434,699 401,121 Investor relations 206,300 194,754 38,567 Legal 195,971 233,243 520,698 Listing and share registry 163,949 152,954 164,949 Superannuation 180,092 141,539 62,647 Travel and entertainment 196,369 105,535 9,459 Share-based payment expenses - options 3,299 104,753 94,890 Share-based payment expenses - performance rights - 122,201 - Occupancy 24,122 - - Other 178,635 104,904 241,880 4,555,726 4,220,905 3,524,388 Research and development expenses Consulting 277,128 111,530 230,684 Project research and development 5,098,333 2,480,615 427,031 5,375,461 2,592,145 657,715 Selling and marketing expenses Selling 379,406 192,878 57,854 Marketing 1,310,979 474,926 113,472 Distribution costs 339,263 259,619 245,211 2,029,648 927,423 416,537

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Expense [Abstract]
Schedule of Unused Tax Losses for which no Deferred Tax Asset Recognized	30 June 30 June 2024 2023 Unused tax losses for which no deferred tax asset has been recognized 59,447,397 52,625,541 Potential tax benefit 25% (2023: 25%) 14,861,849 13,156,385
Schedule of Income Tax Expense	Numerical reconciliation of income tax expense to prima facie tax payable 30 June 30 June Loss from continuing operations before income tax expense (6,936,957 ) (3,786,507 ) Tax at the Australian tax rate of 25% (2023: 25%) (1,734,239 ) (946,627 ) Tax effect of amounts which are not deductible (taxable) in calculating taxable income: R&D tax incentive (191,245 ) (98,219 ) Accounting expenditure subject to R&D tax incentive 439,644 225,791 Share-based payments 825 56,738 Net impact of other amounts not deductible (taxable) (220,449 ) (453,038 ) Subtotal (1,705,464 ) (1,215,355 ) Tax losses and other timing differences for which no deferred tax asset is recognized 1,705,464 1,215,355 Income tax expense - -

Key Management Personnel Comp_2

Key Management Personnel Compensation (Tables)	12 Months Ended
	Jun. 30, 2024
Key Management Personnel Compensation [Abstract]
Schedule of Key Management Personnel Compensation	The aggregate compensation made to Directors and Other Key Management Personnel of the Company is set out below: 30 June 30 June 30 June A$ A$ A$ Key Management Personnel Compensation Short-term employee benefits 1,637,409 1,394,154 636,673 Post-employment benefits 158,080 5,283 44,489 Long-term benefits 10,607 8,110 15,168 Share-based payment expenses to KMP and their related entities 3,300 200,753 94,890 Total Key Management Personnel Compensation 1,809,396 1,608,300 791,220

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Jun. 30, 2024
Loss per Share [Abstract]
Schedule of Loss Per Share	30 June 30 June 30 June A$ A$ A$ Basic/Diluted loss per share (in cents) 3.04 1.66 1.25 a) Net loss used in the calculation of basic and diluted loss per share 6,936,957 3,786,507 2,854,254 b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic and diluted loss per share 227,860,641 227,798,346 227,579,684

Financial Assets and Financia_2

Financial Assets and Financial Liabilities (Tables)	12 Months Ended
	Jun. 30, 2024
Financial Assets and Financial Liabilities [Abstract]
Schedule of Cash and Cash Equivalents	Cash and cash equivalents 30 June 30 June A$ A$ Cash at Bank and in hand: Cash at bank and in hand 11,657,315 17,159,764 Total 11,657,315 17,159,764
Schedule of Trade and Other Receivables	Trade and other receivables 30 June 30 June A$ A$ Current Trade receivables 1 607,436 46,949 Loss allowance (16,233 ) (27,920 ) Accrued income – Australian R&D tax incentive refund 2 768,370 398,391 Other income receivables – R&D grants 3 28,000 - Total 1,387,573 417,420 1 All trade receivables are non-interest bearing. 2 Receivables from the Australian Tax Office in relation to R&D tax incentive refund for the year. 3 The group has recognized $28,000 of EMDG grant in other income receivable for the current financial year (2023: nil
Schedule of Recurring Fair Value Measurements	Financial assets mandatorily measured at FVPL include the following: 30 June 30 June Notes A$ A$ Current Ateria share options 8(c)(iii) - 221,620 Ateria contingent consideration receivable 8(c)(iii) - 1,612,414 - 1,834,034 (i) Recognized fair value measurements Recurring fair value measurements Notes Level 2 Level 3 Total $ $ $ At 30 June 2024 Financial assets Ateria share options - - - Ateria contingent consideration receivable - - - Total financial assets - - - Recurring fair value measurements Notes Level 2 Level 3 Total At 30 June 2023 $ $ $ Financial assets Ateria share options 221,620 - 221,620 Ateria contingent consideration receivable - 1,612,414 1,612,414 Total financial assets 221,620 1,612,414 1,834,034
Schedule of Losses Were Recognised in Profit or Loss	During the year, the following losses were recognised in profit or loss: 30 June 30 June 30 June A$ A$ A$ Fair value gains/(losses) to financial assets (557,676 ) (523,666 ) - Reconciliation Level 2 Level 3 Total $ $ $ Financial assets Balance at acquisition date 221,620 1,612,414 1,834,034 Fair value gains/(losses) to financial assets (221,620 ) (336,056 ) (557,676 ) Net foreign exchange gains - 20,595 20,595 Share of loss from associates* - (101,603 ) (101,603 ) Issue of Ateria contingent shares* - (1,195,350 ) (1,195,350 ) Balance at 30 June 2024 - - - * Note:
Schedule of the Fair Value of the Share Options	As at 30 June 2023, the fair value of Ateria share options were determined using the following inputs: Value date Expiry date Exercise price No. of Share price Expected Dividend Risk- free Fair value 2023-06-30 2023-07-31 £ 2.00 735,000 £ 1.85 100.00 % 0.00 % 4.18 % £ 0.1583
Schedule of Other Current Assets	Other current assets 30 June 30 June A$ A$ Prepayments 96,841 158,151 Total 96,841 158,151
Schedule of Trade and Other Payables	Trade and other payables 30 June 30 June Current Trade payables 648,851 790,919 Accrued expenses 1,445,451 394,026 Other payables 41,550 7,824 Total 2,135,852 1,192,769
Schedule of Deferred Income	Deferred income 30 June 30 June Current Deferred grant income - 698,195 Total - 698,195

Non-financial assets and liab_2

Non-financial assets and liabilities (Tables)	12 Months Ended
	Jun. 30, 2024
Non-financial assets and liabilities [Abstract]
Schedule of Property, Plant and Equipment	(a) Property, plant and equipment Plant and Furniture, Right-of-use Total At 30 June 2022 Cost or fair value 364,856 35,042 229,031 628,929 Accumulated depreciation (345,343 ) (34,905 ) (21,945 ) (402,193 ) Net book amount 19,513 137 207,086 226,736 Year ended 30 June 2023 Opening net book amount 19,513 137 207,086 226,736 Additions 7,067 672 14,320 22,059 Depreciation charge (7,203 ) (131 ) (41,328 ) (48,662 ) Closing net book amount 19,377 678 180,078 200,133 At 30 June 2023 Cost or fair value 371,923 35,714 243,351 650,988 Accumulated depreciation (352,546 ) (35,036 ) (63,273 ) (450,855 ) Net book amount 19,377 678 180,078 200,133 Year ended 30 June 2024 Opening net book amount 19,377 678 180,078 200,133 Additions 195 - - 195 Depreciation charge (5,576 ) (339 ) (40,066 ) (45,981 ) Closing net book amount 13,996 339 140,012 154,347 At 30 June 2024 Cost or fair value 372,118 35,714 243,351 651,183 Accumulated depreciation (358,122 ) (35,375 ) (103,339 ) (496,836 ) Net book amount 13,996 339 140,012 154,347
Schedule of Inventories	(b) Inventories 30 June 2024 30 June 2023 Current Non- Total Current Non- Total Raw materials and stores (Colostrum) 139,745 669,285 809,030 - 1,108,256 1,108,256 Work in progress 683,850 683,850 444,905 111,390 556,295 Finished goods (Travelan and Protectyn) 610,020 - 610,020 394,381 - 394,381 Other inventories 150,993 - 150,993 682 - 682 1,584,608 669,285 2,253,893 839,968 1,219,646 2,059,614 (c) Employee benefit obligations 2024 2023 Current Non- Total Current Non- Total Leave obligations (i) 265,952 8,605 274,557 237,328 1,882 239,210 Performance bonus 256,619 - 256,619 52,080 - 52,080 522,571 8,605 531,176 289,408 1,882 291,290
Schedule of Balance Sheet	The balance sheet shows the following amounts relating to leases: 30 June 30 June Right-of-use assets 1 Properties 140,012 180,078 140,012 180,078 Lease liabilities 2 Current 40,556 38,767 Non-current 132,941 150,325 173,497 189,092 1. Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet. 2. Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet.
Schedule of Statement of Profit or Loss	The statement of profit or loss shows the following amounts relating to leases: 2024 2023 Depreciation charge of right-of-use assets Properties 40,066 41,328 40,066 41,328 Interest expense (included in finance cost) 7,576 9,652 Expense relating to short-term leases (included in other expenses) - - Expense relating to leases of low-value assets that are not short-term leases (included in other expenses) - - Expense relating to variable lease payments not included in lease liabilities (included in other expenses) - - Cash paid for principal payments 47,293 35,015

Interests in Other Entities (Ta

Interests in Other Entities (Tables)	12 Months Ended
	Jun. 30, 2024
Interests in Other Entities [Abstract]
Schedule of Subsidiaries	The country of incorporation or registration is also their principal place of business. Percentage of Country of 30 June 30 June Parent Entity: Immuron Limited Australia — — Subsidiaries of Immuron Limited: Immuron Inc. USA 100 % 100 % Anadis EPS Pty Ltd Australia 100 % 100 % IMC Canada Ltd. Canada 100 % 100 % Name of entity Place of business/ country of incorporation Ownership interest held by the group 2024 2023 Ateria Health Limited United Kingdom 23.6 17.5
Schedule of Financial Information for Associates	Summarised financial information for associates 30 June 30 June The group’s share of loss for the period (1,456,019 ) (324,340 ) Recognised in: Note 30 June 30 June Share of loss for the period - 23.6% (2023: 17.5%) (291,711 ) (324,340 ) Impairment of investment in associate 8(c)(i) (1,164,308 ) (1,456,019 ) (324,340 ) Reconciliation of the consolidated entity’s carrying amount 2024 2023 Opening carrying amount 159,066 - Initial Investment in Ateria Health Limited - 404,117 Acquisition of shares (Note 8(c) (iii)) 1,195,350 79,289 Share of loss in Ateria for the period (190,108 ) (324,340 ) Impairment of investment in Ateria (1,164,308 ) - - 159,066

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Jun. 30, 2024
Share Capital [Abstract]
Schedule of Share Capital	2024 2023 2022 2024 2023 2022 Ordinary shares Fully paid 227,998,346 227,798,346 227,798,346 88,504,043 88,436,263 88,436,263 227,998,346 227,798,346 227,798,346 88,504,043 88,436,263 88,436,263
Schedule of Ordinary Shares	Movements in ordinary shares: Details Number of Total Balance at 30 June 2021 227,246,596 88,361,303 Issue at $0.12 under ESOP Plan (2021-11-05) 333,000 39,960 Issue at $0.16 in lieu of payment for services (2021-12-17) 218,750 35,000 Less: Transaction costs arising on share issues - - Balance at 30 June 2022 227,798,346 88,436,263 Less: Transaction costs arising on share issues - - Balance at 30 June 2023 227,798,346 88,436,263 Issue at $0.12 on exercise of unlisted options (2024-03-12) 200,000 67,780 Balance at 30 June 2024 227,998,346 88,504,043

Other Reserves (Tables)

Other Reserves (Tables)	12 Months Ended
	Jun. 30, 2024
Other Reserves [Abstract]
Schedule of Other Reserves	The following table shows a breakdown of the consolidated statement of financial position line item ‘other reserves’ and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table. Notes Share-based Foreign Total other At 1 July 2021 3,360,128 106,514 3,466,642 Currency translation differences - 6,708 6,708 Other comprehensive income - 6,708 6,708 Transactions with owners in their capacity as owners Options and warrants issued/expensed 14(ii) 54,930 - 54,930 Options and warrants lapsed/expired 14(ii) (361,861 ) - (361,861 ) At 30 June 2022 3,053,197 113,222 3,166,419 Notes Share-based Foreign Total other At 1 July 2022 3,053,197 113,222 3,166,419 Currency translation differences - (1,012 ) (1,012 ) Other comprehensive income - (1,012 ) (1,012 ) Transactions with owners in their capacity as owners Options and warrants issued/expensed 14(ii) 104,753 - 104,753 Options and warrants lapsed/expired 14(ii) (156,392 ) - (156,392 ) Performance rights issued/expensed 14(ii) 122,201 - 122,201 At 30 June 2023 3,123,759 112,210 3,235,969 Notes Share-based Foreign Total other At 1 July 2023 3,123,759 112,210 3,235,969 Currency translation differences - 2,266 2,266 Other comprehensive income - 2,266 2,266 Transactions with owners in their capacity as owners Options and warrants exercised 14(ii) (43,780 ) - (43,780 ) Options issued in the period (net of adjustments) 14(ii) (11,932 ) - (11,932 ) Lapse of unexercised options 14(ii) (23,957 ) - (23,957 ) Unlisted options issued/expensed 14(ii) 15,231 - 15,231 At 30 June 2024 3,059,321 114,476 3,173,797
Schedule of Movements in Options, Warrants and Performance Rights	Movements in options/warrants and performance rights: Details Notes Number of Total Balance at 30 June 2021 45,309,478 3,360,128 Lapse of unexercised options at $0.50 (2021-07-01) (1,200,000 ) (188,400 ) Issue of ESOP unlisted options at $0.25 (2021-11-05) 1 500,000 18,624 Lapse of unexercised options at $1.94 (2021-11-30) (14,493 ) (28,813 ) Lapse of unexercised options at $1.94 (2022-06-14) (24,721,108 ) (144,648 ) ESOP unlisted options granted at $0.12 (2022-06-27) 1 - 36,306 Balance at 30 June 2022 19,873,877 3,053,197 Share-based payment expenses – options 1 1,430,000 104,753 Lapse of unexercised options (8,424,157 ) (156,392 ) Share-based payment expenses - performance rights 2 - 122,201 Balance at 30 June 2023 12,879,720 3,123,759 Exercise of unlisted options at $0.12 (2024-03-12) (200,000 ) (43,780 ) Performance rights issued 2 1,688,839 0 Lapse of unexercised options (173,600 ) (23,957 ) Unlisted Options Issued/Expensed - 15,231 Options issued in the period (net of adjustments) 3 1,000,000 (11,932 ) Balance at 30 June 2024 15,194,959 3,059,321 1. During the fiscal year 2022, a total of 2,930,000 options were granted to key management personnel. 500,000, 1,000,000 and 1,430,000 options were granted under OIP to Dr. Jerry Kanellos on 26 October 2021, Mr. Paul Brennan on 16 March 2022 and Mr. Steven Lydeamore on 27 June 2022, respectively. 1,430,000 options have been issued to Mr. Steven Lydeamore in July 2022. 1,000,000 options granted to Mr. Brennan upon his appointment are subject to shareholders’ approval after the current reporting period. 2. During the fiscal year 2023, performance rights with a total value of $122,201 were granted to key management personnel and staff as part of their performance bonus. 1,688,839 performance rights were subsequently issued after the reporting period, on 12 July 2023. In which, 1,147,083 and 179,664 performance rights were issued to Mr. Steven Lydeamore and Dr. Jerry Kanellos as part of their fiscal year 2023 performance bonus of $83,000 and $13,000, respectively. These performance rights have nil exercise price, exercisable on issue and expiring on 12 July 2027. 3. 1,000,000 options were granted to Mr. Paul Brennan upon his appointment March 16, 2022, but were subject to shareholder approval that was not obtained until 2023. The options have been expensed over the vesting period from when the service period commenced and Immuron have revised the estimate of the fair value at the grant date. Of the $(11,932) adjustment, $(12,896) relates to the difference between the estimated fair value and the grant date fair value of these options. The fair value at the shareholder approval date was determined using the Black-Scholes option pricing model and takes into account the exercise price, the term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, risk-free interest rate for the term of the security and certain probability assumptions. The offsetting $965 relates to options issued for Dr. Jeannette Joughin.

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Information for the Reportable Segments	The segment information for the reportable segments for the year ended June 30, 2024 is as follows: Research Hyper-immune Corporate Total 2024 A$ A$ A$ A$ Hyper-immune products revenue - 4,902,865 - 4,902,865 Cost of sales of goods - (1,566,068 ) - (1,566,068 ) Gross profit - 3,336,797 - 3,336,797 Other income 3,364,439 43,760 - 3,408,199 Fair value gains/(losses)to financial assets - - (557,676 ) (557,676 ) Net foreign exchange gains/(losses) - - (27,603 ) (27,603 ) Movement in inventory provision - - - - General and administrative expenses (460,251 ) (3,565 ) (4,091,910 ) (4,555,726 ) Research and development expenses (5,375,461 ) - - (5,375,461 ) Selling and marketing expenses - (2,029,648 ) - (2,029,648 ) Operating profit/(loss) (2,471,273 ) 1,347,344 (4,667,184 ) (5,801,118 ) Finance income - - 327,756 327,756 Finance costs - - (7,576 ) (7,576 ) Share of loss from associates - - (1,456,019 ) (1,456,019 ) Income tax expense - - - - Profit/(loss) for the year (2,471,273 ) 1,347,344 (5,813,028 ) (6,936,957 ) Assets Segment assets 768,370 2,845,096 11,936,503 15,549,969 Total assets 768,370 2,845,096 11,936,503 15,549,969 Liabilities Segment liabilities 604,018 206,524 2,029,983 2,840,525 Total liabilities 604,018 206,524 2,029,983 2,840,525 The segment information for the reportable segments for the year ended June 30, 2023 is as follows: Research Hyper-immune Corporate Total 2023 A$ A$ A$ A$ Hyper-immune products revenue - 1,804,705 - 1,804,705 Cost of sales of goods - (495,558 ) - (495,558 ) Gross profit - 1,309,147 - 1,309,147 Other income 2,551,813 39,685 - 2,591,498 Fair value gains/(losses)to financial assets - - (523,666 ) (523,666 ) Net foreign exchange gains/(losses) - - 363,724 363,724 Movement in inventory provision - 430,932 - 430,932 General and administrative expenses (460,251 ) 26,256 (3,786,910 ) (4,220,905 ) Research and development expenses (2,592,145 ) - - (2,592,145 ) Selling and marketing expenses - (927,423 ) - (927,423 ) Operating profit/(loss) (500,583 ) 878,597 (3,946,852 ) (3,568,838 ) Finance income - - 116,323 116,323 Finance costs - - (9,652 ) (9,652 ) Share of loss from associates - - (324,340 ) (324,340 ) Income tax expense - - - - Profit/(loss) for the year (500,583 ) 878,597 (4,164,521 ) (3,786,507 ) Assets Segment assets 398,391 2,078,643 19,511,148 21,988,182 Total assets 398,391 2,078,643 19,511,148 21,988,182 Liabilities Segment liabilities 604,018 206,524 1,560,804 2,371,346 Total liabilities 604,018 206,524 1,560,804 2,371,346 The segment information for the reportable segments for the year ended June 30, 2022 is as follows: Research Hyper-immune Corporate Total 2022 A$ A$ A$ A$ Hyper-immune products revenue - 765,193 - 765,193 Cost of sales of goods - (241,691 ) - (241,691 ) Gross profit - 523,502 - 523,502 Other income 933,140 24,585 - 957,725 Net foreign exchange gains/(losses) - - 247,558 247,558 General and administrative expenses - (164,087 ) (3,360,301 ) (3,524,388 ) Research and development expenses (657,715 ) - - (657,715 ) Selling and marketing expenses - (416,537 ) - (416,537 ) Operating profit/(loss) 275,425 (32,537 ) (3,112,743 ) (2,869,855 ) Finance income - - 21,785 21,785 Finance costs - - (6,184 ) (6,184 ) Profit/(loss) for the year 275,425 (32,537 ) (3,097,142 ) (2,854,254 ) Assets Segment assets 257,500 1,688,910 22,909,414 24,855,824 Total assets 257,500 1,688,910 22,909,414 24,855,824 Liabilities Segment liabilities 7,053 150,151 1,521,219 1,678,423 Total liabilities 7,053 150,151 1,521,219 1,678,423
Schedule of Information on Geographical Regions	The group derives revenue from the transfer of hyper-immune products at a point in time in the following major product lines and geographical regions: Travelan Protectyn Australia United States Canada Australia Total 2024 A$ A$ A$ A$ A$ Hyper-immune products revenue 3,702,876 1,075,614 80,888 43,487 4,902,865 Revenue from external customers 3,702,876 1,075,614 80,888 43,487 4,902,865 Travelan Protectyn Australia United States Canada Australia Total 2023 A$ A$ A$ A$ A$ Hyper-immune products revenue 1,100,725 642,819 1,201 59,960 1,804,705 Revenue from external customers 1,100,725 642,819 1,201 59,960 1,804,705 Travelan Protectyn Australia United States Canada Australia Total 2022 A$ A$ A$ A$ A$ Hyper-immune products revenue 143,378 501,228 63,172 57,415 765,193 Revenue from external customers 143,378 501,228 63,172 57,415 765,193
Schedule of Major Customers	During the years ended June 30, 2024, 2023 and 2022, the Company had the following major customers in the hyper-immune product segment with revenues amounting to 10 percent or more of total group revenues: 2024 2023 2022 Customer A 2,308,425 626,107 99,792 Customer B 957,076 - - Customer C 842,173 223,504 34,020 Customer D 552,509 236,437 - Customer E - 465,614 253,803 Customer F - - 263,137 4,660,183 1,551,662 650,752

Cash Flow Information (Tables)

Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2024
Cash Flow Information [Abstract]
Schedule of Reconciliation of Cash Flow From Operations with Loss After Income Tax	Reconciliation of cash flow from operations with loss after income tax 30 June 30 June 30 June Net Loss for the Year (6,936,957 ) (3,786,507 ) (2,854,254 ) Adjustments for Depreciation expense 45,981 48,662 26,613 Lease modification - - 15,993 Distribution costs - - 35,000 Expected credit losses (11,687 ) 19,111 8,809 Finance costs 7,576 9,652 6,184 Finance income (327,756 ) (116,323 ) (21,785 ) Share of loss from associates 1,456,019 Leave provision expense 44,863 27,235 45,470 Share-based payment expenses 3,299 226,954 94,890 Unrealized net foreign currency gains (76,771 ) (422,881 ) (234,793 ) Change in operating assets and liabilities: Add decrease in trade and other receivables (958,466 ) 226,365 (336,998 ) Add (increase) / decrease in inventories (194,279 ) (776,100 ) 275,605 Add (increase) / decrease in other operating assets 71,353 414,249 (494,143 ) Add (increase) / decrease in financial assets 557,676 848,006 Add (decrease) / increase in trade and other payables 890,102 31,876 285,616 Add (decrease) / increase in other operating liabilities (451,092 ) 654,506 - (5,880,139 ) (2,595,195 ) (3,147,793 )

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Jun. 30, 2024
Notes and other explanatory information [abstract]
Schedule of Options Granted Under OIP	Set out below are summaries of all listed and unlisted options, including those issued under OIP: 2024 2023 2022 Average Number of Average Number of options Average Number of As at 1 July 0.27 12,879,720 0.37 19,873,877 0.31 45,309,478 Granted during the year 0.19 2,000,000 0.12 1,430,000 0.25 500,000 Exercised during the year 0.12 (200,000 ) - - - - Forfeited/lapsed during the year 0.18 (173,600 ) 0.48 (8,424,157 ) 0.27 (25,935,601 ) As at 30 June 0.26 14,506,120 0.27 12,879,720 0.37 19,873,877 Vested and exercisable at 30 June 0.27 13,346,386 0.27 12,610,802 0.37 19,538,877
Schedule of Share Options Outstanding	Share options outstanding at the end of the year have the following expiry date and exercise prices: Exercise Share Share Share Grant date Expiry (A$ unless 30 June 30 June 30 June 2018-03-15 2023-03-15 0.468 - - 7,897,647 2017-06-09 (warrants) 2022-06-08 USD 0.3125 - - - 2018-03-15 2023-03-15 0.585 - - 526,510 2019-05-23 (warrants) 2024-05-23 USD 0.125 - 173,600 173,600 2019-07-16 (warrants) 2024-07-16 USD 0.125 116,120 116,120 116,120 2018-07-13 2021-07-01 0.500 - - - 2019-11-06 2024-02-10 0.500 - - - 2020-10-29 2024-04-14 0.12 7,900,000 8,100,000 8,100,000 2020-07-24 (warrants) 2025-07-21 USD 0.5859 2,560,000 2,560,000 2,560,000 2021-10-26 2025-10-26 0.25 500,000 500,000 500,000 2022-06-27 2026-06-27 0.12 1,430,000 1,430,000 - 2023-11-21 2027-11-21 0.25 1,000,000 - - 2024-06-19 2028-06-19 0.13 1,000,000 - - Total 14,506,120 12,879,720 19,873,877 Weighted average remaining contractual life of options outstanding at end of period 2.01 1.35 1.54
Schedule of Options Granted Under OIP	The model inputs for options granted under OIP during the year ended June 30, 2024 included: Share price Fair value Exercise at grant Risk- free date per price No. of date Expected Dividend interest option Grant date Expiry date (A$) options (A$) volatility yield rate (A$) 2023-11-21 2027-11-21 0.25 1,000,000 0.08 119.21 % 0.00 % 4.09 % 0.0511 2024-06-19 2028-06-19 0.13 1,000,000 * 0.09 90.42 % 0.00 % 3.97 % 0.0524 2,000,000 * 1,000,000 options granted to Dr. Jeannette Joughin are subject to shareholder approval at the upcoming AGM on 26 November 2024. The model inputs for options granted under OIP during the year ended June 30, 2022 included: Share price Fair value Exercise at grant Risk- free date per price No. of date Expected Dividend interest option Grant date Expiry date (A$) options (A$) volatility yield rate (A$) 2021-10-26 2025-10-26 0.25 500,000 0.12 131.70 % 0.00 % 0.69 % 0.0886 2022-06-27 2026-06-27 0.12 1,430,000 * 0.07 128.10 % 0.00 % 3.31 % 0.0530 2022-03-15 2026-06-27 0.12 1,000,000 * 0.07 128.10 % 0.00 % 3.31 % 0.0530 2,930,000 * 1,430,000 options granted to Mr. Steven Lydeamore on 27 June 2022 and subsequently issued after the reporting period, on 1 July 2022. 1,000,000 options granted to Mr. Paul Brennan on 15 March 2022.
Schedule of Total Expenses Arising from Share-Based Payment Transactions	Total expenses arising from share-based payment transactions recognized during the period were as follows: 2024 2023 2022 Options issued under OIP 3,299 104,753 54,930 Shares issued under OIP - - 39,960 Performance rights issued under OIP 1 - 122,201 - 3,299 226,954 94,890 1 It was agreed that performance bonus for selected employees for the year ended 30 June 2023 would be paid in performance rights rather than cash. Performance rights to be issued to employees are long-term incentives under OIP.

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Schedule of Information About Other Related Party Transactions	The following transactions occurred with related parties: 2024 2023 2022 Amounts settled in cash or shares for goods and services Purchases of various goods and services from entities controlled by key management personnel (i) 102,293 99,667 154,364 Legal services by key management personnel (ii) - - 20,000 Other (iii) 17,325 17,065 - Aggregate amounts of each of the above types of other transactions with key management personnel of Immuron Limited: 2024 A$ 2023 A$ 2022 A$ Amounts settled in cash or shares during the period Rental of an office suite from Wattle Laboratories Pty Ltd 47,293 44,667 42,364 Services rendered by Grandlodge Capital Pty Ltd 55,000 55,000 112,000 102,293 99,667 154,364
Schedule of Outstanding Balances Transactions with Related Parties	The following balances are outstanding at the end of the reporting period in relation to transactions with related parties: 2024 A$ 2023 A$ 2022 A$ Current payables (purchases of goods and services) Entities controlled by key management personnel 55,000 55,000 77,000

Financial Risk Management Obj_2

Financial Risk Management Objectives and Policies (Tables)	12 Months Ended
	Jun. 30, 2024
Financial Risk Management Objectives and Policies [Abstract]
Schedule of Foreign Currency Risk	The group’s exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollars, was as follows: 2024 2023 USD CAD HKD USD CAD HKD Cash and cash equivalents 2,721,574 13,453 - 4,770,507 14,293 - Trade receivables 36,297 88,459 - 46,821 - - Trade payables 250,865 42,047 18,308 577,644 1,841 24,636 Total exposure 3,008,736 143,959 18,308 5,394,972 16,134 24,636
Schedule of Exchange Rates	Impact on loss for Impact on other 2024 2023 2024 2023 USD/AUD exchange rate – change by 4.8% (2023: 5.8%) 144,419 312,908 5,495 37
Schedule of Loss Allowance	On that basis, the loss allowance as at June 30, 2024 was determined as follows for trade receivables: Days past due 30 June 2024 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 1 0.23 % 1.80 % 0.00 % 5.83 % 16.15 % 50.90 % - Gross carrying amount 1 463,334 75,725 8,458 4,183 42,631 13,105 607,436 Loss allowance 1,073 1,361 - 244 6,885 6,670 16,233 1. Trade receivables balance of $607,436 represents 12.39% of $4,902,865 revenue from contracts with customers of the current fiscal year. Based on the expected credit losses assessment and review of individual accounts, $16,233 was provided for. Subsequent to 30 June 2024, above 90% of the trade receivables balance has since been received in cash. On that basis, the loss allowance as at June 30, 2023 was determined as follows for trade receivables: Days past due 30 June 2023 Current 1-30 31-60 61-90 91-120 121+ Total Expected credit loss rate 1 59.42 % 0.00 % 61.57 % 66.75 % 0.00 % 0.00 % Gross carrying amount 1 44,345 - 3,294 (690 ) - - 46,949 Loss allowance 26,352 - 2,028 (460 ) - - 27,920 1. Trade receivables balance of $46,949 represents 2.6% of $1,804,705 revenue from contracts with customers of the current fiscal year. Based on the expected credit losses assessment and review of individual accounts, $27,920 was provided for. Subsequent to 30 June 2023, above 90% of the trade receivables balance has since been received in cash.
Schedule of Contractual Discounted Cash Flows	The amounts disclosed in the table are the contractual discounted cash flows. Contractual maturities Less than 6 - 12 Between Between Over Total Carrying of financial liabilities A$ A$ A$ A$ A$ A$ A$ At 30 June 2024 Trade and other payables 648,851 - - - - 648,851 648,851 Lease liabilities 20,278 20,278 46,342 86,598 - 173,497 173,497 Total 664,129 20,278 46,343 86,598 - 822,348 822,348 At 30 June 2023 Trade and other payables 798,743 - - - - 798,743 798,743 Lease liabilities 19,165 19,602 40,556 109,769 - 189,092 189,092 Total 817,908 19,602 40,556 109,769 - 987,835 987,835

Parent Entity Financial Infor_2

Parent Entity Financial Information (Tables)	12 Months Ended
	Jun. 30, 2024
Parent Entity Financial Information [Abstract]
Schedule of Individual Financial Statements	The individual financial statements for the parent entity show the following aggregate amounts: 2024 2023 Balance sheet Current assets 14,724,947 20,348,996 Non-current assets 859,110 1,580,065 Total assets 15,584,057 21,929,061 Current liabilities 2,775,925 2,213,981 Non-current liabilities 141,510 152,207 Total liabilities 2,917,435 2,366,188 Shareholders’ equity Share capital 88,504,043 88,436,263 Reserves - - Share-based payments 3,059,321 3,123,759 Accumulated losses (78,896,742 ) (71,997,149 ) 12,666,662 19,562,873 Loss for the year 6,899,593 3,700,827 Total comprehensive loss 6,899,593 3,700,827

Auditors' Remuneration (Tables)

Auditors' Remuneration (Tables)	12 Months Ended
	Jun. 30, 2024
Auditors Remuneration [Abstract]
Schedule of Audit Service	The following table sets forth, for each of the years indicated, the fees billed by Grant Thornton Audit Pty Ltd. Year Ended 2024 2023 Audit and review of financial statements 1 254,350 241,583 254,350 241,583 1 Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.
Schedule of All Other Fees	Year Ended 2024 2023 EMDG grant consulting services 7,210 3,000 7,210 3,000
Schedule of Consolidated Entity Disclosure Statement	Consolidated Entity Disclosure Statement: Name of entity Type of entity Trustee, partner, or participant in joint venture % of share capital held Country of incorporation Australian resident or foreign resident (for tax purpose) Foreign tax jurisdiction(s) of foreign residents Immuron Limited Body corporate n/a n/a Australia Australian n/a Immuron Inc. Body corporate n/a 100 United States Foreign United States Immuron Canada Ltd Body corporate n/a 100 Canada Foreign Canada Anadis ESP Pty Ltd Body corporate n/a 100 Australia Australian n/a

Summary of Material Accountin_2

Summary of Material Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2024 AUD ($)	Jun. 30, 2023 AUD ($)
Summary of Material Accounting Policies [Line Items]
Number of reportable segments	2
Rebates percentage	15%
Plant and Equipment [Member] | Bottom of range [Member]
Summary of Material Accounting Policies [Line Items]
Estimated useful lives	2 years
Plant and Equipment [Member] | Top of range [Member]
Summary of Material Accounting Policies [Line Items]
Estimated useful lives	5 years
Furniture, fittings and equipment [Member] | Bottom of range [Member]
Summary of Material Accounting Policies [Line Items]
Estimated useful lives	3 years
Furniture, fittings and equipment [Member] | Top of range [Member]
Summary of Material Accounting Policies [Line Items]
Estimated useful lives	15 years
Right-of-use assets [Member]
Summary of Material Accounting Policies [Line Items]
Estimated useful lives	3 years
Medical Technology Enterprise Consortium [Member]
Summary of Material Accounting Policies [Line Items]
R&D grant (in Dollars)	$ 2,599,458
Henry M Jackson Foundation [Member]
Summary of Material Accounting Policies [Line Items]
R&D grant (in Dollars)		$ 2,158,936

Critical Accounting Estimates_2

Critical Accounting Estimates and Judgments (Details)	Jun. 30, 2024 AUD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 AUD ($)
Critical Accounting Estimates and Judgments [Abstract]
Raw materials (in Dollars)	$ 809,030	$ 139,745	$ 1,108,256
Raw material	$ 669,285		$ 1,108,256

Revenue and Other Income (Detai

Revenue and Other Income (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Medical Technology Enterprise Consortium [Member]
Revenue and Other Income [Line Items]
Recognize income	$ 2,599,458	$ 2,158,936

Revenue and Other Income (Det_2

Revenue and Other Income (Details) - Schedule of Revenue and Other Income - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Revenue from Operating Activities
Revenue from contracts with customers at a point in time	$ 4,902,865	$ 1,804,705	$ 765,193
Total Revenue from Operating Activities	4,902,865	1,804,705	765,193
Grant Income
Australian R&D tax incentive refund	764,981	392,877	257,500
MTEC R&D grant	2,599,458	2,158,936	369,045
HJF R&D grant			306,595
EMDG grant	28,000	28,000
Other income	15,760	11,685	24,585
Total Grant Income	3,408,199	2,591,498	957,725
Other Gains/(Losses) – Net
Fair value gains/(losses) to financial assets	(557,676)	(523,666)
Net foreign exchange gains/(losses)	(27,603)	363,724	247,558
Movement in inventory provision		$ 430,932

Expenses (Details) - Schedule o

Expenses (Details) - Schedule of Expenses - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Schedule of Expenses [Line Items]
Share-based payment expenses - options	$ 3,299	$ 226,954	$ 94,890
Total general and administrative expenses	4,555,726	4,220,905	3,524,388
Total research and development expenses	5,375,461	2,592,145	657,715
Total selling and marketing expenses	2,029,648	927,423	416,537
General and administrative expenses [Member]
Schedule of Expenses [Line Items]
Accounting and audit	576,540	657,970	499,331
Bad debts		2,376
Consulting	120,851	23,241	226,710
Depreciation	45,981	48,662	42,606
Employee benefits	2,353,625	1,874,963	1,212,721
Expected credit losses	(11,687)	19,111	8,809
Insurance	321,679	434,699	401,121
Investor relations	206,300	194,754	38,567
Legal	195,971	233,243	520,698
Listing and share registry	163,949	152,954	164,949
Superannuation	180,092	141,539	62,647
Travel and entertainment	196,369	105,535	9,459
Share-based payment expenses - options	3,299	104,753	94,890
Share-based payment expenses - performance rights		122,201
Occupancy	24,122
Other	178,635	104,904	241,880
Research and development expenses [Member]
Schedule of Expenses [Line Items]
Consulting	277,128	111,530	230,684
Project research and development	5,098,333	2,480,615	427,031
Selling and marketing expenses [Member]
Schedule of Expenses [Line Items]
Selling	379,406	192,878	57,854
Marketing	1,310,979	474,926	113,472
Distribution costs	$ 339,263	$ 259,619	$ 245,211

Income Tax Expense (Details) -

Income Tax Expense (Details) - Schedule of Unused Tax Losses for which no Deferred Tax Asset Recognized - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Unused Tax Losses for which No Deferred Tax Asset Recognized [Abstract]
Unused tax losses for which no deferred tax asset has been recognized	$ 59,447,397	$ 52,625,541
Potential tax benefit	$ 14,861,849	$ 13,156,385

Income Tax Expense (Details) _2

Income Tax Expense (Details) - Schedule of Unused Tax Losses for which no Deferred Tax Asset Recognized (Parentheticals)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Unused Tax Losses for which No Deferred Tax Asset Recognized [Abstract]
Potential tax benefit, percentage	25%	25%

Income Tax Expense (Details) _3

Income Tax Expense (Details) - Schedule of Income Tax Expense - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Income Tax Expense [Abstract]
Loss from continuing operations before income tax expense	$ (6,936,957)	$ (3,786,507)	$ (2,854,254)
Tax at the Australian tax rate	(1,734,239)	(946,627)
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:
R&D tax incentive	(191,245)	(98,219)
Accounting expenditure subject to R&D tax incentive	439,644	225,791
Share-based payments	825	56,738
Net impact of other amounts not deductible (taxable)	(220,449)	(453,038)
Subtotal	(1,705,464)	(1,215,355)
Tax losses and other timing differences for which no deferred tax asset is recognized	1,705,464	1,215,355
Income tax expense

Income Tax Expense (Details) _4

Income Tax Expense (Details) - Schedule of Income Tax Expense (Parentheticals)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Expense [Abstract]
Tax at the Australian tax rate, percentage	25%	25%

Key Management Personnel Comp_3

Key Management Personnel Compensation (Details) - Schedule of Key Management Personnel Compensation - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Key Management Personnel Compensation
Short-term employee benefits	$ 1,637,409	$ 1,394,154	$ 636,673
Post-employment benefits	158,080	5,283	44,489
Long-term benefits	10,607	8,110	15,168
Share-based payment expenses to KMP and their related entities	3,300	200,753	94,890
Total Key Management Personnel Compensation	$ 1,809,396	$ 1,608,300	$ 791,220

Loss per Share (Details) - Sche

Loss per Share (Details) - Schedule of Loss Per Share - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Loss per Share [Abstract]
Basic loss per share (in cents)	$ 3.04	$ 1.66	$ 1.25
a) Net loss used in the calculation of basic and diluted loss per share	$ 6,936,957	$ 3,786,507	$ 2,854,254
b) Weighted average number of ordinary shares outstanding during the period used in the calculation of basic loss per share	227,860,641	227,798,346	227,579,684

Loss per Share (Details) - Sc_2

Loss per Share (Details) - Schedule of Loss Per Share (Parentheticals) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Loss per Share [Abstract]
Diluted loss per share	$ 3.04	$ 1.66	$ 1.25
Weighted average number of ordinary shares outstanding during the period used in the calculation of diluted loss per share	227,860,641	227,798,346	227,579,684

Financial Assets and Financia_3

Financial Assets and Financial Liabilities (Details)			12 Months Ended
	Feb. 22, 2024 shares	Feb. 28, 2023 £ / shares shares	Jun. 30, 2024 AUD ($) $ / shares shares	Jun. 30, 2024 USD ($)	Jun. 30, 2024 GBP (£)	Jun. 30, 2023 AUD ($) $ / shares	Jun. 30, 2023 GBP (£)	Jun. 30, 2022 AUD ($) $ / shares
Financial Assets and Financial Liabilities [Line Items]
Other income
Total exercise price				$ 965
Expire date			Jul. 31, 2023	Jul. 31, 2023	Jul. 31, 2023
Received shares | shares	471,306
Share price | (per share)		£ 1.85	$ 0.27			$ 0.27		$ 0.37
Expected number of shares to be received | shares		457,577
R&D grant			$ 5,375,461			$ 2,592,145		$ 657,715
Ateria [Member]
Financial Assets and Financial Liabilities [Line Items]
Revenue | £							£ 1,000,000
Medical Technology Enterprise Consortium [Member]
Financial Assets and Financial Liabilities [Line Items]
Other income			28,000
R&D grant			$ 1,901,263
FVPL [Member]
Financial Assets and Financial Liabilities [Line Items]
Share options | shares			735,000
Total exercise price | £					£ 1,470,000
Received shares | shares	471,306

Financial Assets and Financia_4

Financial Assets and Financial Liabilities (Details) - Schedule of Cash and Cash Equivalents	Jun. 30, 2024 AUD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2024 HKD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2023 HKD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 AUD ($)
Cash at Bank and in hand:
Cash at bank and in hand	$ 11,657,315				$ 17,159,764
Total	$ 11,657,315	$ 2,721,574	$ 13,453		$ 17,159,764	$ 4,770,507	$ 14,293		$ 22,110,278	$ 25,047,281

Financial Assets and Financia_5

Financial Assets and Financial Liabilities (Details) - Schedule of Trade and Other Receivables - AUD ($)		Jun. 30, 2024	Jun. 30, 2023
Current
Trade receivables	[1]	$ 607,436	$ 46,949
Loss allowance		(16,233)	(27,920)
Accrued income – Australian R&D tax incentive refund	[2]	768,370	398,391
Other income receivables – R&D grants	[3]	28,000
Total		$ 1,387,573	$ 417,420
[1] All trade receivables are non-interest bearing. Receivables from the Australian Tax Office in relation to R&D tax incentive refund for the year. The group has recognized $28,000 of EMDG grant in other income receivable for the current financial year (2023: nil

Financial Assets and Financia_6

Financial Assets and Financial Liabilities (Details) - Schedule of Recurring Fair Value Measurements - AUD ($)	Jun. 30, 2024	Jun. 30, 2023
Current
Ateria share options		$ 221,620
Ateria contingent consideration receivable		1,612,414
Total financial assets		1,834,034
Level 2 [Member]
Current
Ateria share options		221,620
Ateria contingent consideration receivable
Total financial assets		221,620
Level 3 [Member]
Current
Ateria share options
Ateria contingent consideration receivable		1,612,414
Total financial assets		$ 1,612,414

Financial Assets and Financia_7

Financial Assets and Financial Liabilities (Details) - Schedule of Losses Were Recognised in Profit or Loss - Financial Asset [Member] - AUD ($)		1 Months Ended			12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2024
Schedule of Losses Were Recognised in Profit or Loss [Line Items]
Fair value gains/(losses) to financial assets		$ (557,676)	$ (523,666)		$ (557,676)
Financial assets
Balance at acquisition date					1,834,034
Net foreign exchange gains					20,595
Share of loss from associates	[1]				(101,603)
Issue of Ateria contingent shares	[1]				(1,195,350)
Balance at 30 June 2024			1,834,034
Level 2 [Member]
Schedule of Losses Were Recognised in Profit or Loss [Line Items]
Fair value gains/(losses) to financial assets					(221,620)
Financial assets
Balance at acquisition date					221,620
Net foreign exchange gains
Share of loss from associates	[1]
Issue of Ateria contingent shares	[1]
Balance at 30 June 2024			221,620
Level 3 [Member]
Schedule of Losses Were Recognised in Profit or Loss [Line Items]
Fair value gains/(losses) to financial assets					(336,056)
Financial assets
Balance at acquisition date					1,612,414
Net foreign exchange gains					20,595
Share of loss from associates	[1]				(101,603)
Issue of Ateria contingent shares	[1]				(1,195,350)
Balance at 30 June 2024			$ 1,612,414
[1] Note:

Financial Assets and Financia_8

Financial Assets and Financial Liabilities (Details) - Schedule of the Fair Value of the Share Options - Ateria [Member]	12 Months Ended
	Jun. 30, 2024 £ / shares $ / shares
Financial Assets and Financial Liabilities (Details) - Schedule of the Fair Value of the Share Options [Line Items]
Value date	Jun. 30, 2023
Expiry date	Jul. 31, 2023
Exercise price (in Pounds per share)	£ 2
No. of options	735,000
Share price at grant date (in Pounds per share)	£ 1.85
Expected volatility	100%
Dividend yield	0%
Risk- free interest rate	4.18%
Fair value at grant date per option (in Dollars per share) | $ / shares	£ 0.1583

Financial Assets and Financia_9

Financial Assets and Financial Liabilities (Details) - Schedule of Other Current Assets - AUD ($)	Jun. 30, 2024	Jun. 30, 2023
Schedule of Other Current Assets [Abstract]
Prepayments	$ 96,841	$ 158,151
Total	$ 96,841	$ 158,151

Financial Assets and Financi_10

Financial Assets and Financial Liabilities (Details) - Schedule of Trade and Other Payables - AUD ($)	Jun. 30, 2024	Jun. 30, 2023
Current
Trade payables	$ 648,851	$ 790,919
Accrued expenses	1,445,451	394,026
Other payables	41,550	7,824
Total	$ 2,135,852	$ 1,192,769

Financial Assets and Financi_11

Financial Assets and Financial Liabilities (Details) - Schedule of Deferred Income - AUD ($)	Jun. 30, 2024	Jun. 30, 2023
Current
Deferred grant income		$ 698,195
Total		$ 698,195

Non-financial assets and liab_3

Non-financial assets and liabilities (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Non-financial assets and liabilities [Abstract]
Provision for finished goods
Total leave provision	265,952	237,328
Cash outflow for leases	$ (7,576)	$ (9,652)

Non-financial assets and liab_4

Non-financial assets and liabilities (Details) - Schedule of Property, Plant and Equipment - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Schedule of Property, Plant and Equipment [Line Items]
Net book amount	$ 154,347	$ 200,133
Opening net book amount	200,133
Closing net book amount	154,347	200,133
Property, plant and equipment [member]
Schedule of Property, Plant and Equipment [Line Items]
Net book amount	13,996	19,377	$ 19,513
Opening net book amount	19,377	19,513
Additions	195	7,067
Depreciation charge	(5,576)	(7,203)
Closing net book amount	13,996	19,377
Furniture, fittings and equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Net book amount	339	678	137
Opening net book amount	678	137
Additions		672
Depreciation charge	(339)	(131)
Closing net book amount	339	678
Right-of-use assets [member]
Schedule of Property, Plant and Equipment [Line Items]
Net book amount	140,012	180,078	207,086
Opening net book amount	180,078	207,086
Additions		14,320
Depreciation charge	(40,066)	(41,328)
Closing net book amount	140,012	180,078
Gross carrying amount [member]
Schedule of Property, Plant and Equipment [Line Items]
Cost or fair value	651,183	650,988	628,929
Accumulated depreciation	(496,836)	(450,855)	(402,193)
Net book amount	154,347	200,133	226,736
Opening net book amount	200,133	226,736
Additions	195	22,059
Depreciation charge	(45,981)	(48,662)
Closing net book amount	154,347	200,133
Gross carrying amount [member] | Property, plant and equipment [member]
Schedule of Property, Plant and Equipment [Line Items]
Cost or fair value	372,118	371,923	364,856
Gross carrying amount [member] | Furniture, fittings and equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Cost or fair value	35,714	35,714	35,042
Gross carrying amount [member] | Right-of-use assets [member]
Schedule of Property, Plant and Equipment [Line Items]
Cost or fair value	243,351	243,351	229,031
Accumulated depreciation, amortisation and impairment [member] | Property, plant and equipment [member]
Schedule of Property, Plant and Equipment [Line Items]
Accumulated depreciation	(358,122)	(352,546)	(345,343)
Accumulated depreciation, amortisation and impairment [member] | Furniture, fittings and equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Accumulated depreciation	(35,375)	(35,036)	(34,905)
Accumulated depreciation, amortisation and impairment [member] | Right-of-use assets [member]
Schedule of Property, Plant and Equipment [Line Items]
Accumulated depreciation	$ (103,339)	$ (63,273)	$ (21,945)

Non-financial assets and liab_5

Non-financial assets and liabilities (Details) - Schedule of Inventories	12 Months Ended
	Jun. 30, 2024 AUD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2024 USD ($)
Schedule of Inventories [Line Items]
Raw materials and stores (Colostrum)	$ 809,030	$ 1,108,256	$ 139,745
Work in progress	683,850	556,295
Finished goods (Travelan and Protectyn)	610,020	394,381
Other inventories	150,993	682
Total inventories	2,253,893	2,059,614
Leave obligations	274,557	239,210
Performance bonus	256,619	52,080
Total employee benefit obligations	531,176	291,290
Current [Member]
Schedule of Inventories [Line Items]
Raw materials and stores (Colostrum)	139,745
Work in progress	683,850	444,905
Finished goods (Travelan and Protectyn)	610,020	394,381
Other inventories	150,993	682
Total inventories	1,584,608	839,968
Leave obligations	265,952	237,328
Performance bonus	256,619	52,080
Total employee benefit obligations	522,571	289,408
Non- Current [Member]
Schedule of Inventories [Line Items]
Raw materials and stores (Colostrum)	669,285	1,108,256
Work in progress		111,390
Finished goods (Travelan and Protectyn)
Other inventories
Total inventories	669,285	1,219,646
Leave obligations	8,605	1,882
Performance bonus
Total employee benefit obligations	$ 8,605	$ 1,882

Non-financial assets and liab_6

Non-financial assets and liabilities (Details) - Schedule of Balance Sheet - AUD ($)		Jun. 30, 2024	Jun. 30, 2023
Right-of-use assets1
Properties	[1]	$ 140,012	$ 180,078
Total right-of-use assets	[1]	140,012	180,078
Lease liabilities2
Current	[2]	40,556	38,767
Non-current	[2]	132,941	150,325
Total lease liabilities	[2]	$ 173,497	$ 189,092
[1] Included in the line item ‘property, plant and equipment’ in the consolidated balance sheet. Included in the line items ‘other current liabilities’ and ‘other non-current liabilities’ in the consolidated balance sheet.

Non-financial assets and liab_7

Non-financial assets and liabilities (Details) - Schedule of Statement of Profit or Loss - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Depreciation charge of right-of-use assets
Properties	$ 40,066	$ 41,328
Total	40,066	41,328
Interest expense (included in finance cost)	7,576	9,652
Expense relating to short-term leases (included in other expenses)
Expense relating to leases of low-value assets that are not short-term leases (included in other expenses)
Expense relating to variable lease payments not included in lease liabilities (included in other expenses)
Cash paid for principal payments	$ 47,293	$ 35,015

Interests in Other Entities (De

Interests in Other Entities (Details) - USD ($)		12 Months Ended
	Feb. 22, 2024	Jun. 30, 2024	Jun. 30, 2023	Nov. 25, 2022
Interests in Other Entities [Abstract]
Acquired percentage		23.60%	17.50%	17.50%
Received shares	471,306
Impairment loss		$ 1,456,019
Recoverable amount		$ 0

Interests in Other Entities (_2

Interests in Other Entities (Details) - Schedule of Subsidiaries	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Immuron Limited [Member]
Parent Entity:
Place of business/ country of incorporation	Australia
Ownership interest held by the group
Immuron Inc [Member]
Parent Entity:
Place of business/ country of incorporation	USA
Ownership interest held by the group	100%	100%
Anadis EPS Pty Ltd [Member]
Parent Entity:
Place of business/ country of incorporation	Australia
Ownership interest held by the group	100%	100%
IMC Canada Ltd [Member]
Parent Entity:
Place of business/ country of incorporation	Canada
Ownership interest held by the group	100%	100%
Ateria Health Limited [Member]
Parent Entity:
Place of business/ country of incorporation	United Kingdom
Ownership interest held by the group	23.60%	17.50%

Interests in Other Entities (_3

Interests in Other Entities (Details) - Schedule of Financial Information for Associates - Immuron Inc [Member] - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Financial Information for Associates [Line Items]
The group’s share of loss for the period	$ (1,456,019)	$ (324,340)
Share of loss for the period - 23.6% (2023: 17.5%)	(291,711)	(324,340)
Impairment of investment	(1,164,308)
Investments accounted for using the equity method		159,066
Share of loss from associates	(1,456,019)	(324,340)
Opening carrying amount	159,066
Initial Investment in Ateria Health Limited		404,117
Acquisition of shares (Note 8(c) (iii))	1,195,350	79,289
Share of loss in Ateria for the period	$ (190,108)	$ (324,340)

Interests in Other Entities (_4

Interests in Other Entities (Details) - Schedule of Financial Information for Associates (Parentheticals)	Jun. 30, 2024	Jun. 30, 2023	Nov. 25, 2022
Schedule of Financial Information for Associates [Line Items]
Share of loss for the period	23.60%	17.50%	17.50%

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) - AUD ($)	Jun. 30, 2024	Jun. 30, 2023
Contingent Liabilities and Commitments [Abstract]
Contingent liabilities or commitments

Share Capital (Details) - Sched

Share Capital (Details) - Schedule of Share Capital - AUD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share Capital [Abstract]
Ordinary shares	227,998,346	227,798,346	227,798,346
Ordinary shares, value	$ 88,504,043	$ 88,436,263	$ 88,436,263
Ordinary shares, Fully paid, shares	227,998,346	227,798,346	227,798,346
Ordinary shares, Fully paid, value	$ 88,504,043	$ 88,436,263	$ 88,436,263

Share Capital (Details) - Sch_2

Share Capital (Details) - Schedule of Ordinary Shares - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share Capital [Abstract]
Balance at beginning	227,798,346	227,798,346	227,246,596
Balance at beginning	$ 88,436,263	$ 88,436,263	$ 88,361,303
Issue at $0.12 under ESOP Plan (2021-11-05)			333,000
Issue at $0.12 under ESOP Plan (2021-11-05)			$ 39,960
Issue at $0.16 in lieu of payment for services (2021-12-17)			218,750
Issue at $0.16 in lieu of payment for services (2021-12-17)			$ 35,000
Less: Transaction costs arising on share issues
Less: Transaction costs arising on share issues
Issue at $0.12 on exercise of unlisted options (2024-03-12)	200,000
Issue at $0.12 on exercise of unlisted options (2024-03-12)	$ 67,780
Balance at ending	227,998,346	227,798,346	227,798,346
Balance at ending	$ 88,504,043	$ 88,436,263	$ 88,436,263

Other Reserves (Details)

Other Reserves (Details)					12 Months Ended
	Jul. 31, 2022 shares	Jul. 27, 2022 shares	Mar. 16, 2022 shares	Oct. 26, 2021 shares	Jun. 30, 2024 AUD ($) shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2022 shares
Other Reserves [Line Items]
Granted option							2,930,000
Number of shares unlisted option					1,000,000	1,000,000
Performance rights, description					During the fiscal year 2023, performance rights with a total value of $122,201 were granted to key management personnel and staff as part of their performance bonus. 1,688,839 performance rights were subsequently issued after the reporting period, on 12 July 2023. In which, 1,147,083 and 179,664 performance rights were issued to Mr. Steven Lydeamore and Dr. Jerry Kanellos as part of their fiscal year 2023 performance bonus of $83,000 and $13,000, respectively. These performance rights have nil exercise price, exercisable on issue and expiring on 12 July 2027.	During the fiscal year 2023, performance rights with a total value of $122,201 were granted to key management personnel and staff as part of their performance bonus. 1,688,839 performance rights were subsequently issued after the reporting period, on 12 July 2023. In which, 1,147,083 and 179,664 performance rights were issued to Mr. Steven Lydeamore and Dr. Jerry Kanellos as part of their fiscal year 2023 performance bonus of $83,000 and $13,000, respectively. These performance rights have nil exercise price, exercisable on issue and expiring on 12 July 2027.
Granted shares			2,023
Adjustments between the estimated fair value and grant date | $					$ (11,932)
Options issued (in Dollars) | $						$ 965
Dr. Jerry Kanellos [Member]
Other Reserves [Line Items]
Granted option				500,000
Mr.Paul Brennan [Member]
Other Reserves [Line Items]
Granted option			1,000,000
Mr. Steven Lydeamore [Member]
Other Reserves [Line Items]
Granted option		1,430,000
Options issued	1,430,000
Mr.Paul Brennan [Member]
Other Reserves [Line Items]
Adjustments between the estimated fair value and grant date | $						$ (12,896)

Other Reserves (Details) - Sche

Other Reserves (Details) - Schedule of Other Reserves - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share-based payments [Member]
Schedule of Other Reserves [Line Items]
Balance at beginning	$ 3,123,759	$ 3,053,197	$ 3,360,128
Currency translation differences
Other comprehensive income
Options and warrants exercised	(43,780)
Options issued in the period (net of adjustments)	(11,932)
Options and warrants issued/expensed		104,753	54,930
Options and warrants lapsed/expired	(23,957)	(156,392)	(361,861)
Unlisted options issued/expensed	15,231
Performance rights issued/expensed		122,201
Balance at ending	3,059,321	3,123,759	3,053,197
Foreign currency translation [Member]
Schedule of Other Reserves [Line Items]
Balance at beginning	112,210	113,222	106,514
Currency translation differences	2,266	(1,012)	6,708
Other comprehensive income	2,266	(1,012)	6,708
Options and warrants exercised
Options issued in the period (net of adjustments)
Options and warrants issued/expensed
Options and warrants lapsed/expired
Unlisted options issued/expensed
Performance rights issued/expensed
Balance at ending	114,476	112,210	113,222
Total other reserves [Member]
Schedule of Other Reserves [Line Items]
Balance at beginning	3,235,969	3,166,419	3,466,642
Currency translation differences	2,266	(1,012)	6,708
Other comprehensive income	2,266	(1,012)	6,708
Options and warrants exercised	(43,780)
Options issued in the period (net of adjustments)	(11,932)
Options and warrants issued/expensed		104,753	54,930
Options and warrants lapsed/expired	(23,957)	(156,392)	(361,861)
Unlisted options issued/expensed	15,231
Performance rights issued/expensed		122,201
Balance at ending	$ 3,173,797	$ 3,235,969	$ 3,166,419

Other Reserves (Details) - Sc_2

Other Reserves (Details) - Schedule of Movements in Options, Warrants and Performance Rights - Warrants [member]		12 Months Ended
		Jun. 30, 2024 AUD ($) shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 AUD ($) shares	Jun. 30, 2022 AUD ($) shares
Other Reserves (Details) - Schedule of Movements in Options, Warrants and Performance Rights [Line Items]
Balance beginning		12,879,720	12,879,720	19,873,877	45,309,478
Balance beginning (in Dollars) | $		$ 3,123,759		$ 3,053,197	$ 3,360,128
Balance ending		15,194,959	15,194,959	12,879,720	19,873,877
Balance ending (in Dollars) | $		$ 3,059,321		$ 3,123,759	$ 3,053,197
Lapse of unexercised options at $0.50 (2021-07-01)					(1,200,000)
Lapse of unexercised options at $0.50 (2021-07-01) (in Dollars) | $					$ (188,400)
Issue of ESOP unlisted options at $0.25 (2021-11-05)	[1]				500,000
Issue of ESOP unlisted options at $0.25 (2021-11-05) (in Dollars) | $	[1]				$ 18,624
Lapse of unexercised options at $1.94 (2021-11-30)					(14,493)
Lapse of unexercised options at $1.94 (2021-11-30) (in Dollars) | $					$ (28,813)
Lapse of unexercised options at $1.94 (2022-06-14)					(24,721,108)
Lapse of unexercised options at $1.94 (2022-06-14) (in Dollars) | $					$ (144,648)
ESOP unlisted options granted at $0.12 (2022-06-27)	[1]
ESOP unlisted options granted at $0.12 (2022-06-27) (in Dollars) | $	[1]				$ 36,306
Share-based payment expenses – options	[1]			1,430,000
Share-based payment expenses – options (in Dollars) | $	[1]			$ 104,753
Exercise of unlisted options at $0.12 (2024-03-12)		(200,000)	(200,000)
Exercise of unlisted options at $0.12 (2024-03-12)		(43,780)	(43,780)
Performance rights issued	[2]	1,688,839	1,688,839
Performance rights issued (in Dollars) | $	[2]	$ 0
Lapse of unexercised options		(173,600)	(173,600)	(8,424,157)
Lapse of unexercised options (in Dollars) | $		$ (23,957)		$ (156,392)
Unlisted Options Issued/Expensed
Unlisted Options Issued/Expensed (in Dollars) | $			$ 15,231
Options issued in the period (net of adjustments)	[3]	1,000,000	1,000,000
Options issued in the period (net of adjustments) (in Dollars) | $	[3]	$ (11,932)
Share-based payment expenses - performance rights	[2]
Share-based payment expenses - performance rights (in Dollars) | $	[2]			$ 122,201
[1] During the fiscal year 2022, a total of 2,930,000 options were granted to key management personnel. 500,000, 1,000,000 and 1,430,000 options were granted under OIP to Dr. Jerry Kanellos on 26 October 2021, Mr. Paul Brennan on 16 March 2022 and Mr. Steven Lydeamore on 27 June 2022, respectively. 1,430,000 options have been issued to Mr. Steven Lydeamore in July 2022. 1,000,000 options granted to Mr. Brennan upon his appointment are subject to shareholders’ approval after the current reporting period. During the fiscal year 2023, performance rights with a total value of $122,201 were granted to key management personnel and staff as part of their performance bonus. 1,688,839 performance rights were subsequently issued after the reporting period, on 12 July 2023. In which, 1,147,083 and 179,664 performance rights were issued to Mr. Steven Lydeamore and Dr. Jerry Kanellos as part of their fiscal year 2023 performance bonus of $83,000 and $13,000, respectively. These performance rights have nil exercise price, exercisable on issue and expiring on 12 July 2027. 1,000,000 options were granted to Mr. Paul Brennan upon his appointment March 16, 2022, but were subject to shareholder approval that was not obtained until 2023. The options have been expensed over the vesting period from when the service period commenced and Immuron have revised the estimate of the fair value at the grant date. Of the $(11,932) adjustment, $(12,896) relates to the difference between the estimated fair value and the grant date fair value of these options. The fair value at the shareholder approval date was determined using the Black-Scholes option pricing model and takes into account the exercise price, the term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, risk-free interest rate for the term of the security and certain probability assumptions. The offsetting $965 relates to options issued for Dr. Jeannette Joughin.

Segment Reporting (Details)

Segment Reporting (Details)	Jun. 30, 2024
Segment Reporting [Abstract]
Number of segment	2

Segment Reporting (Details) - S

Segment Reporting (Details) - Schedule of Segment Information for the Reportable Segments - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of operating segments [line items]
Hyper-immune products revenue	$ 4,902,865	$ 1,804,705	$ 765,193
Cost of sales of goods	(1,566,068)	(495,558)	(241,691)
Gross profit	3,336,797	1,309,147	523,502
Other income	3,408,199	2,591,498	957,725
Fair value gains/(losses)to financial assets	(557,676)	(523,666)
Net foreign exchange gains/(losses)	(27,603)	363,724	247,558
Movement in inventory provision		430,932
General and administrative expenses	(4,555,726)	(4,220,905)	(3,524,388)
Research and development expenses	(5,375,461)	(2,592,145)	(657,715)
Selling and marketing expenses	(2,029,648)	(927,423)	(416,537)
Operating profit/(loss)	(5,801,118)	(3,568,838)	(2,869,855)
Finance income	327,756	116,323	21,785
Finance costs	(7,576)	(9,652)	(6,184)
Share of loss from associates	(1,456,019)	(324,340)
Income tax expense
Profit/(loss) for the year	(6,936,957)	(3,786,507)	(2,854,254)
Assets
Segment assets	15,549,969	21,988,182	24,855,824
Total assets	15,549,969	21,988,182	24,855,824
Liabilities
Segment liabilities	2,840,525	2,371,346	1,678,423
Total liabilities	2,840,525	2,371,346	1,678,423
Research and Development [Member]
Disclosure of operating segments [line items]
Hyper-immune products revenue
Cost of sales of goods
Gross profit
Other income	3,364,439	2,551,813	933,140
Fair value gains/(losses)to financial assets
Net foreign exchange gains/(losses)
Movement in inventory provision
General and administrative expenses	(460,251)	(460,251)
Research and development expenses	(5,375,461)	(2,592,145)	(657,715)
Selling and marketing expenses
Operating profit/(loss)	(2,471,273)	(500,583)	275,425
Finance income
Finance costs
Share of loss from associates
Income tax expense
Profit/(loss) for the year	(2,471,273)	(500,583)	275,425
Assets
Segment assets	768,370	398,391	257,500
Total assets	768,370	398,391	257,500
Liabilities
Segment liabilities	604,018	604,018	7,053
Total liabilities	604,018	604,018	7,053
Hyperimmune Products [Member]
Disclosure of operating segments [line items]
Hyper-immune products revenue	4,902,865	1,804,705	765,193
Cost of sales of goods	(1,566,068)	(495,558)	(241,691)
Gross profit	3,336,797	1,309,147	523,502
Other income	43,760	39,685	24,585
Fair value gains/(losses)to financial assets
Net foreign exchange gains/(losses)
Movement in inventory provision		430,932
General and administrative expenses	(3,565)	26,256	(164,087)
Research and development expenses
Selling and marketing expenses	(2,029,648)	(927,423)	(416,537)
Operating profit/(loss)	1,347,344	878,597	(32,537)
Finance income
Finance costs
Share of loss from associates
Income tax expense
Profit/(loss) for the year	1,347,344	878,597	(32,537)
Assets
Segment assets	2,845,096	2,078,643	1,688,910
Total assets	2,845,096	2,078,643	1,688,910
Liabilities
Segment liabilities	206,524	206,524	150,151
Total liabilities	206,524	206,524	150,151
Corporate [Member]
Disclosure of operating segments [line items]
Hyper-immune products revenue
Cost of sales of goods
Gross profit
Other income
Fair value gains/(losses)to financial assets	(557,676)	(523,666)
Net foreign exchange gains/(losses)	(27,603)	363,724	247,558
Movement in inventory provision
General and administrative expenses	(4,091,910)	(3,786,910)	(3,360,301)
Research and development expenses
Selling and marketing expenses
Operating profit/(loss)	(4,667,184)	(3,946,852)	(3,112,743)
Finance income	327,756	116,323	21,785
Finance costs	(7,576)	(9,652)	(6,184)
Share of loss from associates	(1,456,019)	(324,340)
Income tax expense
Profit/(loss) for the year	(5,813,028)	(4,164,521)	(3,097,142)
Assets
Segment assets	11,936,503	19,511,148	22,909,414
Total assets	11,936,503	19,511,148	22,909,414
Liabilities
Segment liabilities	2,029,983	1,560,804	1,521,219
Total liabilities	$ 2,029,983	$ 1,560,804	$ 1,521,219

Segment Reporting (Details) -_2

Segment Reporting (Details) - Schedule of Information on Geographical Regions - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Schedule of Information on Geographical Regions [Line Items]
Hyper-immune products revenue	$ 4,902,865	$ 1,804,705	$ 765,193
Revenue from external customers	4,902,865	1,804,705	765,193
Australia [Member] | Travelan [Member]
Schedule of Information on Geographical Regions [Line Items]
Hyper-immune products revenue	3,702,876	1,100,725	143,378
Revenue from external customers	3,702,876	1,100,725	143,378
Australia [Member] | Protectyn [Member]
Schedule of Information on Geographical Regions [Line Items]
Hyper-immune products revenue	43,487	59,960	57,415
Revenue from external customers	43,487	59,960	57,415
United States [Member] | Travelan [Member]
Schedule of Information on Geographical Regions [Line Items]
Hyper-immune products revenue	1,075,614	642,819	501,228
Revenue from external customers	1,075,614	642,819	501,228
Canada [Member] | Travelan [Member]
Schedule of Information on Geographical Regions [Line Items]
Hyper-immune products revenue	80,888	1,201	63,172
Revenue from external customers	$ 80,888	$ 1,201	$ 63,172

Segment Reporting (Details) -_3

Segment Reporting (Details) - Schedule of Major Customers - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Schedule of Major Customers [Line Items]
Total revenue for major customers	$ 4,660,183	$ 1,551,662	$ 650,752
Customer A [Member]
Schedule of Major Customers [Line Items]
Total revenue for major customers	2,308,425	626,107	99,792
Customer B [Member]
Schedule of Major Customers [Line Items]
Total revenue for major customers	957,076
Customer C [Member]
Schedule of Major Customers [Line Items]
Total revenue for major customers	842,173	223,504	34,020
Customer D [Member]
Schedule of Major Customers [Line Items]
Total revenue for major customers	552,509	236,437
Customer E [Member]
Schedule of Major Customers [Line Items]
Total revenue for major customers		465,614	253,803
Customer F [Member]
Schedule of Major Customers [Line Items]
Total revenue for major customers			$ 263,137

Cash Flow Information (Details)

Cash Flow Information (Details) - Schedule of Reconciliation of Cash Flow From Operations with Loss After Income Tax - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Schedule of Reconciliation of Cash Flow From Operations with Loss After Income Tax [Abstract]
Net Loss for the Year	$ (6,936,957)	$ (3,786,507)	$ (2,854,254)
Adjustments for
Depreciation expense	45,981	48,662	26,613
Lease modification			15,993
Distribution costs			35,000
Expected credit losses	(11,687)	19,111	8,809
Finance costs	7,576	9,652	6,184
Finance income	(327,756)	(116,323)	(21,785)
Share of loss from associates	1,456,019
Leave provision expense	44,863	27,235	45,470
Share-based payment expenses	3,299	226,954	94,890
Unrealized net foreign currency gains	(76,771)	(422,881)	(234,793)
Change in operating assets and liabilities:
Add decrease in trade and other receivables	(958,466)	226,365	(336,998)
Add (increase) / decrease in inventories	(194,279)	(776,100)	275,605
Add (increase) / decrease in other operating assets	71,353	414,249	(494,143)
Add (increase) / decrease in financial assets	557,676	848,006
Add (decrease) / increase in trade and other payables	890,102	31,876	285,616
Add (decrease) / increase in other operating liabilities	(451,092)	654,506
Total	$ (5,880,139)	$ (2,595,195)	$ (3,147,793)

Share-Based Payments (Details)

Share-Based Payments (Details) - shares	Jun. 30, 2024	Jun. 30, 2023	Jun. 27, 2022	Mar. 15, 2022
Ms Jeannette Joughin [Member]
Share-based Payments [Line Items]
Options granted	1,000,000
OIP [Member]
Share-based Payments [Line Items]
Options granted
Mr. Steven Lydeamore [Member]
Share-based Payments [Line Items]
Options granted			1,430,000
Mr.Paul Brennan [Member]
Share-based Payments [Line Items]
Options granted				1,000,000

Share-Based Payments (Details)

Share-Based Payments (Details) - Schedule of Movement in Number of Stock Options Outstanding and Weighted Average Exercise Price	12 Months Ended
	Jun. 30, 2024 $ / shares	Jun. 30, 2023 $ / shares	Jun. 30, 2022 $ / shares	Feb. 28, 2023 £ / shares
Schedule of movement in number of stock options outstanding and weighted average exercise price [Abstract]
Average exercise price per share option, Beginning balance	$ 0.27	$ 0.37	$ 0.31
Number of options, Beginning balance	12,879,720	19,873,877	45,309,478
Average exercise price per share option, Granted during the year	$ 0.19	$ 0.12	$ 0.25
Number of options, Granted during the year	2,000,000	1,430,000	500,000
Average exercise price per share option, Exercised during the year	$ 0.12
Number of options, Exercised during the year	(200,000)
Average exercise price per share option, Forfeited/ lapsed during the year	$ 0.18	$ 0.48	$ 0.27
Number of options,Forfeited/ lapsed during the year	(173,600)	(8,424,157)	(25,935,601)
Average exercise price per share option, Ending balance	$ 0.26	$ 0.27	$ 0.37
Number of options, Ending balance	14,506,120	12,879,720	19,873,877
Average exercise price per share option, Vested and exercisable | (per share)	$ 0.27	$ 0.27	$ 0.37	£ 1.85
Number of options, Vested and exercisable	13,346,386	12,610,802	19,538,877

Share-Based Payments (Details_2

Share-Based Payments (Details) - Schedule of Share Options Outstanding	12 Months Ended
	Jun. 30, 2024 $ / shares	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Schedule of Share Options Outstanding [Line Items]
Share options	14,506,120	12,879,720	19,873,877	45,309,478
Weighted average remaining contractual life of options outstanding at end of period	2 years 3 days	1 year 4 months 6 days	1 year 6 months 14 days
2018-03-15 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Mar. 15, 2023
Exercise price (in Dollars per share)	$ 0.468
Share options			7,897,647
2017-06-09 (warrants) [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Jun. 08, 2022
Exercise price (in Dollars per share)	$ 0.3125
Share options
2018-03-15 One [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Mar. 15, 2023
Exercise price (in Dollars per share)	$ 0.585
Share options			526,510
2019-05-23 (warrants) [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	May 23, 2024
Exercise price (in Dollars per share)	$ 0.125
Share options		173,600	173,600
2019-07-16 (warrants) [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Jul. 16, 2024
Exercise price (in Dollars per share)	$ 0.125
Share options	116,120	116,120	116,120
2018-07-13 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Jul. 01, 2021
Exercise price (in Dollars per share)	$ 0.5
Share options
2019-11-06 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Feb. 10, 2024
Exercise price (in Dollars per share)	$ 0.5
Share options
2020-10-29 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Apr. 14, 2024
Exercise price (in Dollars per share)	$ 0.12
Share options	7,900,000	8,100,000	8,100,000
2020-07-24 (warrants) [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Jul. 21, 2025
Exercise price (in Dollars per share)	$ 0.5859
Share options	2,560,000	2,560,000	2,560,000
2021-10-26 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Oct. 26, 2025
Exercise price (in Dollars per share)	$ 0.25
Share options	500,000	500,000	500,000
2022-06-27 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Jun. 27, 2026
Exercise price (in Dollars per share)	$ 0.12
Share options	1,430,000	1,430,000
2023-11-21 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Nov. 21, 2027
Exercise price (in Dollars per share)	$ 0.25
Share options	1,000,000
2024-06-19 [Member]
Schedule of Share Options Outstanding [Line Items]
Expiry date	Jun. 19, 2028
Exercise price (in Dollars per share)	$ 0.13
Share options	1,000,000

Share-Based Payments (Details_3

Share-Based Payments (Details) - Schedule of Options Granted Under OIP		12 Months Ended
		Jun. 30, 2024 $ / shares	Jun. 30, 2022 $ / shares
Schedule of Options Granted Under OIP [Line Items]
No. of options		2,000,000	2,930,000
2023-11-21 [Member]
Schedule of Options Granted Under OIP [Line Items]
Expiry date		Nov. 21, 2027
Exercise price (in Dollars per share)		$ 0.25
No. of options		1,000,000
Share price at grant date (in Dollars per share)		$ 0.08
Expected volatility		119.21%
Dividend yield		0%
Risk- free interest rate		4.09%
Fair value at grant date per option (in Dollars per share)		$ 0.0511
2024-06-19 [Member]
Schedule of Options Granted Under OIP [Line Items]
Expiry date		Jun. 19, 2028
Exercise price (in Dollars per share)		$ 0.13
No. of options	[1]	1,000,000
Share price at grant date (in Dollars per share)		$ 0.09
Expected volatility		90.42%
Dividend yield		0%
Risk- free interest rate		3.97%
Fair value at grant date per option (in Dollars per share)		$ 0.0524
2021-10-26 [Member]
Schedule of Options Granted Under OIP [Line Items]
Expiry date			Oct. 26, 2025
Exercise price (in Dollars per share)			$ 0.25
No. of options			500,000
Share price at grant date (in Dollars per share)			$ 0.12
Expected volatility			131.70%
Dividend yield			0%
Risk- free interest rate			0.69%
Fair value at grant date per option (in Dollars per share)			$ 0.0886
2022-06-27 [Member]
Schedule of Options Granted Under OIP [Line Items]
Expiry date			Jun. 27, 2026
Exercise price (in Dollars per share)			$ 0.12
No. of options	[2]		1,430,000
Share price at grant date (in Dollars per share)			$ 0.07
Expected volatility			128.10%
Dividend yield			0%
Risk- free interest rate			3.31%
Fair value at grant date per option (in Dollars per share)			$ 0.053
2022-03-15 [Member]
Schedule of Options Granted Under OIP [Line Items]
Expiry date			Jun. 27, 2026
Exercise price (in Dollars per share)			$ 0.12
No. of options	[2]		1,000,000
Share price at grant date (in Dollars per share)			$ 0.07
Expected volatility			128.10%
Dividend yield			0%
Risk- free interest rate			3.31%
Fair value at grant date per option (in Dollars per share)			$ 0.053
[1] 1,000,000 options granted to Dr. Jeannette Joughin are subject to shareholder approval at the upcoming AGM on 26 November 2024. 1,430,000 options granted to Mr. Steven Lydeamore on 27 June 2022 and subsequently issued after the reporting period, on 1 July 2022.

Share-Based Payments (Details_4

Share-Based Payments (Details) - Schedule of Total Expenses Arising from Share-Based Payment Transactions - AUD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Share-based Payments [Line Items]
Share-based payment transactions expense		$ 3,299	$ 226,954	$ 94,890
Options under OIP [Member]
Share-based Payments [Line Items]
Share-based payment transactions expense		3,299	104,753	54,930
Shares under OIP [Member]
Share-based Payments [Line Items]
Share-based payment transactions expense				39,960
Performance Rights OIP [Member]
Share-based Payments [Line Items]
Share-based payment transactions expense	[1]		$ 122,201
[1] It was agreed that performance bonus for selected employees for the year ended 30 June 2023 would be paid in performance rights rather than cash. Performance rights to be issued to employees are long-term incentives under OIP.

Related Party Transactions (Det

Related Party Transactions (Details)						12 Months Ended
	Dec. 15, 2021 AUD ($)	Jul. 01, 2021 AUD ($)	Jul. 01, 2020 AUD ($)	Jan. 31, 2016 AUD ($)	Jun. 01, 2013 AUD ($) $ / shares	Jun. 30, 2024 AUD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)
Related Party Transactions [Line Items]
Rental expense				$ 38,940
Warehousing, distribution and invoicing services		$ 77,000	$ 70,000			$ 55,000
Additional payable	$ 35,000
Wattle Laboratories Pty Ltd [Member]
Related Party Transactions [Line Items]
Rental expense						$ 47,293		$ 44,667	$ 42,364
Grandlodge Capital Pty Ltd [Member]
Related Party Transactions [Line Items]
Warehousing, distribution and invoicing services					$ 70,000
Price per share (in Dollars per share) | $ / shares					$ 0.16
Chief Operating Officer [Member]
Related Party Transactions [Line Items]
Related party transaction							$ 17,325	$ 17,065

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Information About Other Related Party Transactions - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Amounts settled in cash or shares for goods and services
Total	$ 102,293	$ 99,667	$ 154,364
Purchases of various goods and services from entities controlled by key management personnel [Member]
Amounts settled in cash or shares for goods and services
Total	102,293	99,667	154,364
Legal services by key management personnel [Member]
Amounts settled in cash or shares for goods and services
Total			20,000
Other [Member]
Amounts settled in cash or shares for goods and services
Total	17,325	17,065
Rental of an office suite from Wattle Laboratories Pty Ltd [Member]
Amounts settled in cash or shares for goods and services
Total	47,293	44,667	42,364
Services rendered by Grandlodge Capital Pty Ltd [Member]
Amounts settled in cash or shares for goods and services
Total	$ 55,000	$ 55,000	$ 112,000

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Outstanding Balances Transactions with Related Parties - AUD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Key management personnel of entity or parent [member]
Current payables (purchases of goods and services)
Entities controlled by key management personnel	$ 55,000	$ 55,000	$ 77,000

Financial Risk Management Obj_3

Financial Risk Management Objectives and Policies (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Financial Risk Management Objectives and Policies [Line Items]
Percentage of USD/AUD exchange rate	4.80%	5.80%
Trade receivables balance	$ 607,436	$ 46,949
Percentage of trade receivables balances	90%	90%
Revenue from contracts with customers	$ 4,902,865	$ 1,804,705	$ 765,193
Expected credit losses assessment	$ 16,233	$ 27,920
Trade Receivables [Member]
Financial Risk Management Objectives and Policies [Line Items]
Percentage of trade receivables balances	12.39%	2.60%

Financial Risk Management Obj_4

Financial Risk Management Objectives and Policies (Details) - Schedule of Foreign Currency Risk	Jun. 30, 2024 AUD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CAD ($)	Jun. 30, 2024 HKD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2023 HKD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2021 AUD ($)
Schedule of Foreign Currency Risk [Abstract]
Cash and cash equivalents	$ 11,657,315	$ 2,721,574	$ 13,453		$ 17,159,764	$ 4,770,507	$ 14,293		$ 22,110,278	$ 25,047,281
Trade receivables		36,297	88,459			46,821
Trade payables		250,865	42,047	18,308		577,644	1,841	24,636
Total exposure		$ 3,008,736	$ 143,959	$ 18,308		$ 5,394,972	$ 16,134	$ 24,636

Financial Risk Management Obj_5

Financial Risk Management Objectives and Policies (Details) - Schedule of Exchange Rates - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Impact on loss for the period [Member]
Schedule of Exchange Rates [Line Items]
USD/AUD exchange rate – change by 4.8% (2023: 5.8%)	$ 144,419	$ 312,908
Impact on other components of equity [Member]
Schedule of Exchange Rates [Line Items]
USD/AUD exchange rate – change by 4.8% (2023: 5.8%)	$ 5,495	$ 37

Financial Risk Management Obj_6

Financial Risk Management Objectives and Policies (Details) - Schedule of Exchange Rates (Parentheticals)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Impact on loss for the period [Member]
Schedule of Exchange Rates [Line Items]
Exchange rate	4.80%	5.80%
Impact on other components of equity [Member]
Schedule of Exchange Rates [Line Items]
Exchange rate	4.80%	5.80%

Financial Risk Management Obj_7

Financial Risk Management Objectives and Policies (Details) - Schedule of Loss Allowance - AUD ($)		Jun. 30, 2024		Jun. 30, 2023
Schedule of Loss Allowance [Line Items]
Expected credit loss rate	[1]
Gross carrying amount		$ 607,436	[1]	$ 46,949	[2]
Loss allowance		$ 16,233		$ 27,920
Current [Member]
Schedule of Loss Allowance [Line Items]
Expected credit loss rate		0.23%	[1]	59.42%	[2]
Gross carrying amount		$ 463,334	[1]	$ 44,345	[2]
Loss allowance		$ 1,073		$ 26,352
1-30 [Member]
Schedule of Loss Allowance [Line Items]
Expected credit loss rate		1.80%	[1]	0%	[2]
Gross carrying amount		$ 75,725	[1]		[2]
Loss allowance		$ 1,361
31-60 [Member]
Schedule of Loss Allowance [Line Items]
Expected credit loss rate		0%	[1]	61.57%	[2]
Gross carrying amount		$ 8,458	[1]	$ 3,294	[2]
Loss allowance				$ 2,028
61-90 [Member]
Schedule of Loss Allowance [Line Items]
Expected credit loss rate		5.83%	[1]	66.75%	[2]
Gross carrying amount		$ 4,183	[1]	$ (690)	[2]
Loss allowance		$ 244		$ (460)
91-120 [Member]
Schedule of Loss Allowance [Line Items]
Expected credit loss rate		16.15%	[1]	0%	[2]
Gross carrying amount		$ 42,631	[1]		[2]
Loss allowance		$ 6,885
121+ [Member]
Schedule of Loss Allowance [Line Items]
Expected credit loss rate		50.90%	[1]	0%	[2]
Gross carrying amount		$ 13,105	[1]		[2]
Loss allowance		$ 6,670
[1] Trade receivables balance of $607,436 represents 12.39% of $4,902,865 revenue from contracts with customers of the current fiscal year. Based on the expected credit losses assessment and review of individual accounts, $16,233 was provided for. Subsequent to 30 June 2024, above 90% of the trade receivables balance has since been received in cash. Trade receivables balance of $46,949 represents 2.6% of $1,804,705 revenue from contracts with customers of the current fiscal year. Based on the expected credit losses assessment and review of individual accounts, $27,920 was provided for. Subsequent to 30 June 2023, above 90% of the trade receivables balance has since been received in cash.

Financial Risk Management Obj_8

Financial Risk Management Objectives and Policies (Details) - Schedule of Contractual Discounted Cash Flows - AUD ($)	Jun. 30, 2024	Jun. 30, 2023
Schedule of Contractual Discounted Cash Flows [Line Items]
Trade and other payables	$ 648,851	$ 798,743
Lease liabilities	173,497	189,092
Total	822,348	987,835
Less than 6 months [Member]
Schedule of Contractual Discounted Cash Flows [Line Items]
Trade and other payables	648,851	798,743
Lease liabilities	20,278	19,165
Total	664,129	817,908
6 - 12 months [Member]
Schedule of Contractual Discounted Cash Flows [Line Items]
Trade and other payables
Lease liabilities	20,278	19,602
Total	20,278	19,602
Between 1 and 2 years [Member]
Schedule of Contractual Discounted Cash Flows [Line Items]
Trade and other payables
Lease liabilities	46,342	40,556
Total	46,343	40,556
Between 2 and 5 years [Member]
Schedule of Contractual Discounted Cash Flows [Line Items]
Trade and other payables
Lease liabilities	86,598	109,769
Total	86,598	109,769
Over 5 years [Member]
Schedule of Contractual Discounted Cash Flows [Line Items]
Trade and other payables
Lease liabilities
Total
Total contractual cash flows [Member]
Schedule of Contractual Discounted Cash Flows [Line Items]
Trade and other payables	648,851	798,743
Lease liabilities	173,497	189,092
Total	$ 822,348	$ 987,835

Events Occurring After the Re_2

Events Occurring After the Reporting Date (Details) $ in Millions	Jul. 03, 2024 USD ($)
Non-Adjusting Events After Reporting Period [Member]
Events Occurring After the Reporting Date [Line Items]
Funding facility amount	$ 2

Parent Entity Financial Infor_3

Parent Entity Financial Information (Details) - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Parent Entity Financial Information [Line Items]
Debts
Contingent liabilities
Acquisition of property, plant or equipment

Parent Entity Financial Infor_4

Parent Entity Financial Information (Details) - Schedule of Individual Financial Statements - Parent Company [Member] - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Balance sheet
Current assets	$ 14,724,947	$ 20,348,996
Non-current assets	859,110	1,580,065
Total assets	15,584,057	21,929,061
Current liabilities	2,775,925	2,213,981
Non-current liabilities	141,510	152,207
Total liabilities	2,917,435	2,366,188
Shareholders’ equity
Share capital	88,504,043	88,436,263
Reserves
Share-based payments	3,059,321	3,123,759
Accumulated losses	(78,896,742)	(71,997,149)
Total Shareholders' equity	12,666,662	19,562,873
Loss for the year	6,899,593	3,700,827
Total comprehensive loss	$ 6,899,593	$ 3,700,827

Auditors' Remuneration (Details

Auditors' Remuneration (Details) - Schedule of Audit Service - AUD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Auditors Remuneration [Abstract]
Audit and review of financial statements	[1]	$ 254,350	$ 241,583
Total		$ 254,350	$ 241,583
[1] Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably provide.

Auditors' Remuneration (Detai_2

Auditors' Remuneration (Details) - Schedule of All Other Fees - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of all Other Fees [Line Items]
EMDG grant consulting services	$ 7,210	$ 3,000
EMDG grant consulting services [Member]
Schedule of all Other Fees [Line Items]
EMDG grant consulting services	$ 7,210	$ 3,000

Auditors' Remuneration (Detai_3

Auditors' Remuneration (Details) - Schedule of Consolidated Entity Disclosure Statement	12 Months Ended
	Jun. 30, 2024
Immuron Limited [Member]
Schedule of Consolidated Entity Disclosure Statement [Line Items]
Type of entity	Body corporate
Trustee, partner, or participant in joint venture
% of share capital held
Country of incorporation	Australia
Australian resident or foreign resident (for tax purpose)	Australian
Foreign tax jurisdiction(s) of foreign residents
Immuron Inc. [Member]
Schedule of Consolidated Entity Disclosure Statement [Line Items]
Type of entity	Body corporate
Trustee, partner, or participant in joint venture
% of share capital held	100%
Country of incorporation	United States
Australian resident or foreign resident (for tax purpose)	Foreign
Foreign tax jurisdiction(s) of foreign residents	United States
Immuron Canada Ltd [Member]
Schedule of Consolidated Entity Disclosure Statement [Line Items]
Type of entity	Body corporate
Trustee, partner, or participant in joint venture
% of share capital held	100%
Country of incorporation	Canada
Australian resident or foreign resident (for tax purpose)	Foreign
Foreign tax jurisdiction(s) of foreign residents	Canada
Anadis ESP Pty Ltd [Member]
Schedule of Consolidated Entity Disclosure Statement [Line Items]
Type of entity	Body corporate
Trustee, partner, or participant in joint venture
% of share capital held	100%
Country of incorporation	Australia
Australian resident or foreign resident (for tax purpose)	Australian
Foreign tax jurisdiction(s) of foreign residents